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Abstract 
The search for new inhibitors of neurotransmitter reuptake transporters is currently of 
great interest as this type of compounds may prove to have interesting 
pharmacological properties. Bicifadine has shown antagonistic effect on the serotonin 
and norepinephrine reuptake transporters and was used as a lead compound in the 
development of a series of analogues in this project.  
N
H
Bicifadine  
A four step asymmetric synthesis was developed, and eight analogues were prepared. 
The yields range from modest to excellent, and high enantiomeric excess was 
achieved for all analogues. 
 
Sammendrag 
Den siste tiden har inhibitorer av reopptakstransportører for nevrotransmittere blitt 
viet stor oppmerksomhet. Det er gjort mange forsøk på å finne nye forbindelser, 
ettersom denne typen inhibitorer kan ha interessante farmakologiske egenskaper. 
Bicifadine har antagonistisk effekt på både serotonin- og norepinefrin-
reopptakstransportørene og ble benyttet som ”lead compound” i utviklingen av en 
serie analoger i dette prosjektet. 
En fire-trinns synstese ble utviklet, og åtte analoger ble fremstilt. Utbyttene spenner 
fra moderat til godt, og det enantiomere overskudd var stort for alle analogene.
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Abbreviations 
ACE α-Chloroethyl chloroformate 
ADHD Attention-deficit/hyperactivity disorder 
Boc tert-Butoxycarbonyl 
CNS Central nervous system 
COSY Correlated spectroscopy 
Δ Chemical shift 
d Dublet 
dd Double dublet 
DEPT Distortionless enhancement by polarisation transfer 
DMAP 4-(Dimethylamino)pyridine 
DMF N,N-Dimethylformamide 
ee Enantiomeric excess 
EI Electron ionisation 
Eq Equivalent 
ESI Electrospray ionisation 
esp α,α,α’,α’-Tetramethyl-1,3-benzenedipropanate 
HMQC Heteronuclear multiple quantum correlation 
HR-MS High resolution mass spectrometry 
J Coupling constant 
m Multiplet 
Ms Mesyl; methylsulphonyl 
MS Mass spectrometry 
m/z Mass-to-charge ratio 
NaHMDS Sodium bis(trimethylsilyl)amide 
NMDA N-Methyl-D-aspartate 
NMR Nuclear magnetic resonance spectroscopy 
NRI Selective norepinephrine reuptake inhibitor 
ORTEP Oak Ridge Thermal Ellipsoid Plot 
Pd/C Palladium on charcoal 
PG Protecting group 
PMB p-Methoxybenzyl 
ppm Part per million 
q Quartet 
Rf Retention factor (TLC) 
s Singlet 
SAR Structure activity relationship 
SNRI Serotonin-norepinephrine reuptake inhibitor 
SSRI Selective serotonin reuptake inhibitor 
SNDRI Serotonin-norepinephrine-dopamine reuptake inhibitor 
t Triplet 
td Triple doublet 
tdd Triple double doublet 
THF Tetrahydrofuran 
TLC Thin layer chromatography 
TMA Trimethylacetate 
Ts Tosyl; p-toluenesulphonyl 
Nomenclature 
Most of the compounds prepared in this project are made as a series of analogues. The 
compounds are numbered as shown in Scheme 1. Letters a to m refer to the different 
aromatic groups in each compound according to Table 1. 
 
Scheme 1: The numbering of important compounds in this thesis. 
Table 1: The aromatic substituents in analogues. 
Aryl group Letter 
 
a 
 
b 
 
c 
F
 
d 
 
e 
 
f 
g 
 
h 
Cl
 
i 
 
j 
 
k 
 
l 
 
m   
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Stereochemistry 
Naming 
Prefixes (A)- and (B)- are used to facilitate the comparison of stereochemistry for 
compounds 2-5. The series of compounds originating from (S)-(+)-epichlorohydrin is 
named (A), and the series from (R)-(-)-epichlorohydrin is named (B). The relationship 
between (A)/(B) and absolute stereochemistry is shown in Table 2. 
Table 2: The relationship between (A)/(B) naming and absolute stereochemistry in compounds 2-5. 
Compound (A)/(B) Absolute stereochemistry 
(A)-2 
- v - 
(1S,5R) 
O
Ar
O  (B)-2 (1R,5S) 
(A)-3 (1S,2R) 
 (B)-3 (1R,2S) 
(A)-4 (1S,5R) 
N
Ar
PMB  (B)-4 (1R,5S) 
(A)-5 (1S,5R) 
N
H
Ar
 
(B)-5 (1R,5S) 
 
Drawing 
The following convention has been used to symbolise stereochemistry in drawings of 
compounds that contain one or more stereocentres: 
Symbols Meaning 
Absolute stereochemistry is known, and the compound is enantiomerically pure. 
 
Relative stereochemistry is known, and the compound is enantiomerically pure. 
 
Stereochemistry is of importance, but the compound is a racemic mixture. 
 
Stereochemistry is of no relevance, or the compound is a racemic mixture. 
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1 Introduction 
Medicinal chemistry has experienced an enormous development from the use of 
natural products in folk medicine to the synthesis of highly specific pharmaceutical 
compounds in our modern world. The discovery and development of new drugs often 
involve a lead compound, a compound that has shown interesting biological 
properties.1a Sometimes new lead compounds are found by serendipity, in other 
instances as a result from biological screening or calculation on models. When 
looking for new lead compounds, one may start from a variety of sources, e.g. from 
natural materials, existing drugs or natural ligands. Bicifadine, a compound developed 
by DOV Pharmaceutical as an analgesic, and not yet approved as a pharmaceutical 
compound for use in humans, shows interesting properties as a neurotransmitter 
reuptake inhibitor, and for this reason it was chosen as a lead compound in this 
project.2-5 
1.1 The aim of the project 
• To establish a satisfying synthetic route to enantiomerically pure analogues of 
Bicifadine (1-[4-methylphenyl]-3-azabicyclo[3.1.0]hexane). 
• To synthesise a series of analogues with variation in the aromatic function of 
the molecule. 
• To investigate alternative synthetic routes to the target compounds. 
• To send the target compounds to be tested for biological activity at Lundbeck 
A/S in Copenhagen, Denmark. 
- 2 - 
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2 Biological background 
This chapter will discuss some important concepts that form the biological 
background of the project. A short presentation of the central nervous system is given 
together with a short survey of an important class of biological active compounds, the 
neurotransmitters. The similarity between the neurotransmitters and the target 
compounds is discussed, before the biological interest of the target compounds is 
briefly summarised. 
2.1 Central nervous system 
The central nervous system consists of the brain and the spinal cord. Its most 
important function is to receive, interpret and respond to sensory input. The core 
components of the nervous system are the neurons. They convey the nerve signals as 
an electrical impulse along the axons, the long, thin branch-like arm that allows 
neurons to connect to each other. Between the terminus of the axon on one neuron and 
the dendrite on the next, there is a small gap which cannot conduct the electrical 
signal (Figure 1). This gap is called the synaptic cleft. When the signal reaches the 
end of the axon, neurotransmitters are released into the synaptic cleft, triggering the 
receptors on the adjacent neuron, which then passes the signal on to the next neuron.  
 Figure 1: The synaptic cleft and the transmission of a nerve signal with acetylcholine as the 
neurotransmitter.6  
In order for the receptors to maintain their sensitivity, it is necessary that the 
neurotransmitters are removed from the synaptic cleft when the signal has reached the 
receptors. This is conceived by three main mechanisms: The diffusion of the 
transmitters away from the synaptic cleft, the enzymatic destruction of the 
transmitters, and the reuptake of the transmitters into the axon terminus. The recycling 
of these molecules empties the synaptic cleft for neurotransmitters, as well as 
decreasing the cell’s need to synthesise these molecules. It has been shown that if the 
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reuptake mechanism does not function satisfactorily, the effect of the neurotransmitter 
diminishes. Several diseases are thought to be a result of either too small or too large 
concentration of one or more neurotransmitters in the synaptic cleft, especially 
between neurons in the brain. Among these diseases are Parkinson’s disease, 
Alzheimer’s disease, schizophrenia and bipolar disorder (formerly known as manic-
depressive illness).5, 7-10 These diseases are not very well understood, and researchers 
disagree about the neurotransmitters’ roles. 
2.2 Neurotransmitters 
Neurotransmitters are commonly divided into three main groups: Amino acids, 
peptides and monoamines. In addition, acetylcholine (6, Fig. 2) is recognised as a 
neurotransmitter. It was the first ever to be discovered, but does not fit into any of the 
main groups. Of the monoamines, three are very important and best understood:7 
serotonin (7), L-norepinephrine (8, also known as L-noradrenaline) and dopamine (9, 
Fig. 2). Each transmitter has several receptors to react on, and each year new receptors 
are identified.7 
 
Figure 2: The structure of the neurotransmitters acetylcholine (6), serotonin (7), L-norepinephrine (8) 
and dopamine (9). 
Serotonin is known to regulate sleep, appetite, mood, anger, aggression and body 
temperature, and is suspected to be involved in depressions, anxiety and eating 
disorders.7 L-norepinephrine is known to effect concentration,7 and has been under 
active research because of its link to unipolar or bipolar depressive psychosis,7 but is 
also known to have effect on heart rate, blood pressure and mood. Dopamine affects 
sleep, mood, attention and motivation.7 A connection between dopamine and 
attention-deficit/hyperactivity disorder (ADHD) has been found.10 It has also been 
shown that people suffering from Parkinson’s disease and schizophrenia have 
decreased levels of dopamine in the synaptic cleft.7, 8 
- 5 - 
All the monoamines contain a common moiety: A primary amine connected to an 
aromatic ring by a bridge consisting of two carbon atoms (Figure 3). In addition, 
serotonin, norepinephrine and dopamine all have phenolic hydroxyl groups. 
HO
OH
NH2
OH
8
NH2
 
Figure 3: The common moiety of the monoamines, and the moiety marked in norepinephrine (8) as an 
example. 
Many of the compounds used in medicine because of their central nervous system 
stimulating effect, contain this same moiety. Their mode of action is most often to 
inhibit the reuptake transporters of one, two or all of the three important 
neurotransmitters serotonin, norepinephrine and dopamine. Examples of this include 
Lofepramine, a selective norepinephrine reuptake inhibitor (NRI);11 Venlafaxine, a 
serotonin-norepinephrine reuptake inhibitor (SNRI);12 Prolintane, a serotonin-
dopamine reuptake inhibitor.13 Reuptake inhibitors function by blocking the 
transporter, thereby decreasing the reuptake and increasing the concentration of the 
neurotransmitter in the synaptic cleft. Diseases that are caused by low levels of 
neurotransmitters in the synaptic cleft could potentially be treated by this type of 
compounds. There are several antagonists of this type, and they are often divided into 
groups according to how many reuptake transporters they inhibit. The most common 
antidepressants are selective serotonin reuptake inhibitors (SSRI) or selective 
norepinephrine reuptake inhibitors (NRI). In addition, many compounds are known to 
inhibit two (e.g. serotonin-norepinephrine reuptake inhibitors, SNRI), or even all 
three, of the transporters. There are currently no triple inhibitors approved for 
pharmaceutical use. Bicifadine (1) is normally considered a SNRI, but shows some 
affinity for the dopamine transporter as well.5, 14 It was developed by DOV 
Pharmaceutical as an analgesic, and is currently under clinical trials.4, 14 The fact that 
Bicifadine showed promising results as a reuptake inhibitor, lead us to believe that 
analogues of Bicifadine would be an interesting series to test as reuptake inhibitors. 
Because of the bicyclic carbon skeleton, these compounds are not straightforward to 
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obtain, and represent an interesting synthetic challenge. Biological testing of the 
compounds could hopefully give data for structure-activity relationship (SAR) 
analysis, and might be a way to discover new inhibitors, with selective, double or 
triple affinity. 
2.3 Results from previous biological testing 
Two analogues have been the most important ones so far in biological testing: 
Bicifadine (5c) and DOV 216,303 (1-[3,4-dichlorophenyl]-3-azabicyclo[3.1.0]hexane, 
5h, Figure 4). 
N
H
N
H
Cl
Cl
5c 5h  
Figure 4: The structures of Bicifadine (5c) and DOV316,303 (5h). 
Bicifadine (5c) has been known since the early 1980’s and has shown good results as 
an analgesic.2 The compound is an NMDA (N-methyl-D-aspartate) antagonist.14 This 
means that the analgesic effect is caused by antagonising the NMDA receptor. 
Biological testing of this compound has revealed several important issues: The same 
analgesic effect is achieved with smaller doses compared to aspirin and codeine; few, 
if any, adverse effects have so far been discovered and addiction has not been 
observed, a common problem with opioid analgesics like morphine.3, 5, 14-16 Even 
though Bicifadine has been tested and administrated as a racemic mixture, it is known 
that only the (1R,5S) – (+)-enantiomer is active.2 Bicifadine has lately been shown to 
inhibit the reuptake of serotonin and norepinephrine, as well as a slight affinity for the 
dopamine transporter.5, 14 In nature of being a SNRI, it proved an interesting lead 
compound for our project.  
DOV 216,303 (5h) on the other hand is a triple reuptake inhibitor: It inhibits the 
reuptake of serotonin, norepinephrine and dopamine and is a serotonin-
norepinephrine-dopamine reuptake inhibitor (SNDRI).17 Pharmacological testing has 
- 7 - 
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shown that compound 5h can be administered to humans without any severe adverse 
effects even at plasma concentrations higher than the IC50 value for triple inhibition. 
Phase II testing of the compound indicates at least the same effect as Citalopram, 
which is a selective serotonin reuptake inhibitor (SSRI).  
3 Chemical background 
In this chapter the chemistry of the target compounds is discussed. The importance of 
the carbon skeleton is explained together with some key points about synthesising 
enantiomerically pure compounds. Finally, known analogues of the target compounds 
and published syntheses are summarised. 
3.1 Medicinal chemistry 
Bicifadine (5c, Fig. 5) was chosen as our lead compound for its profound effect on the 
central nervous system (CNS) by mimicking neurotransmitters.3, 14  
 
Figure 5: The structure of Bicifadine 5c. 
We have seen that another analogue of 1-phenyl-3-azabicyclo[3.1.0]hexane (5m) also 
show an antagonistic effect on the reuptake transporters in the central nervous system. 
Probably most of the 1-aryl analogues of 5m will show some antagonistic effect, but 
little is known about the structure activity relationship (SAR). The first SAR testing 
that was reported, showed the relationship between structure and analgesic effect in 
mice.3 Recently, another SAR study was published.5 The study reveals that the 
aromatic group has a profound effect on the compound’s potency as a monoamine 
reuptake inhibitor. The primary aim of the project was to synthesise a collection of 
Bicifadine analogues as enantiomerically pure compounds and test their antagonistic 
effect on the reuptake of serotonin, norepinephrine and dopamine.  
3.2 Why choose a bicyclic compound? 
In the search for compounds with specific biological activity, there are several aspects 
to consider. Most importantly the compound must show high affinity for the desired 
receptor, but it should show only small or no affinity for other receptors, as this might 
- 9 - 
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give rise to unwanted adverse effects. Comparing natural ligands usually gives a 
strong indication of which parts of the molecule are necessary for the biological 
activity, but does not give information about the affinity to other receptors. In the 
previous section one important structural motif was shown (Figure 3, p. 6). It is 
thought that by copying this motive, new serotonin-norepinephrine-dopamine 
reuptake inhibitors (SNDRI) might be discovered, but this moiety has several carbon-
carbon single bonds about which rotation is possible. Because of this, many 
conformers of the compound are possible. When discussing receptors and ligands, it is 
conventional to think that only one of these conformers actually fit the receptor. By 
introducing a bicyclic system, this part of the molecule will have highly constricted 
conformational freedom. This may lead to one of two things: Either this conformation 
is incompatible with the structure of the receptor, meaning that the biological activity 
is strongly diminished or lost altogether; or the conformation fits the receptor to a 
high degree.1b If the latter is the case, hopefully the conformational rigidity of the 
structure will not fit other receptors, but this is of course not always the case. 
3.3 Asymmetric synthesis 
Since many biological receptors are chiral, the need for enantiomerically pure 
compounds when conducting biological testing is imperative. One method is to start 
with an enantiomerically pure starting material. If none of the reactions in the 
synthetic sequence towards the target molecule racemises the compound, and no 
epimerisation takes place at any stage, the product will also be enantiomerically pure. 
This is called first generation asymmetric synthesis, and is the method of choice for 
this work. 
3.4 Known analogues of 1-phenyl-3-azabicyclo[3.1.0]hexane 
(5m) 
1-phenyl-3-azabicyclo[3.1.0]hexane (5m) contains the same moiety as discussed in a 
previous section (Fig. 3, p. 6). Several analogues of this compound has been 
synthesised,2, 4 but few have been tested as reuptake inhibitors.15, 18 These compounds 
were first reported in 1978 because of their analgesic properties.2, 19 At the turn of the 
millennium, the interest was renewed because these compounds showed promising 
results in the treatment of depression20 and chemical dependencies.21 In only a few 
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years several patents have been disclosed regarding synthesis and properties of these 
compounds.22-26  Table 3 shows which of the analogues that have been synthesised as 
enantiomerically pure compounds. 
Table 3: Analogues of 1-phenyl-3-azabicyclo[3.1.0]hexane (5m) that are previously synthesised as 
enantiomerically pure compounds. 
Aryl groups in synthesised analouges of 1-phenyl-3-azabicyclo[3.1.0]hexane (5m) 
 
As both 1S,5R and 1R,5S Only as 1S,5R Only as 1R,5S 
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3.5 Known synthetic routes 
3.5.1 Synthesis via a cyclopropyldiacid 
Several syntheses of Bicifadine analogues have been published.2, 4, 14, 27-29 The earliest, 
published in 1981 by Epstein et al.,2 is a general procedure that has been used to 
synthesise several analogues (Scheme 2). 
MeO2C CO2Me
HO2C CO2HN
H
N
H
10 11 12
13145m
Ph
PhPh
Ph
CO2Me
Br
CO2Me
NaH/Et2O
1. KOH, 85 %, reflux, 6 h
2. HCl (aq)
Urea/xylene
1. Vitride/toluene
reflux, 2 h
O O
MeOH
r.t., 24 h
reflux, 6-20 h2. NaOH (aq)
3. HCl (g), Et2O
 
Scheme 2: Synthesis of 1-phenyl-3-azabicyclo[3.1.0]hexane (5m) as published by Epstein et al.2 
By reacting α-bromophenylacetate (10), which can be synthesised from phenylacetate 
by reaction with N-bromosuccinimide in carbon tetrachloride and a catalytic amount 
of HBr, with methyl acrylate (11) cis-cyclopropane diester 12 is formed (Scheme 1). 
The diacid 13 is formed by alkaline hydrolysis of the ester 12; and the bicyclic system 
14 is formed by reaction with ammonia generated in situ from urea.30 The target 
compound 5m is then reached by reducing the imide 14 with Vitride (sodium bis-(2-
methoxyethoxy)aluminium hydride).  
This route does not allow the synthesis of single enantiomers directly, so resolution of 
the racemic mixture is necessary. The resolution is most preferably done on one of the 
intermediates. By reacting the diacid 13 with an optically active base, a salt is formed 
consisting of two diastereomers (Scheme 3). These can be separated, for instance by 
recrystallisation.2 The compound can then be liberated from the salt to give the pure 
enantiomer. There are several drawbacks to this method: Often the recrystallisation 
- 13 - 
proves difficult; and even if it is possible to achieve pure crystals, the mother liqueur 
usually still contains some of the first enantiomer, meaning that the other enantiomer 
cannot be formed in a straight forward fashion. Several recrystallisations may be 
needed, and also the use of several, potentially costly, optically active bases. 
 
Scheme 3: Example showing the resolution of racemic 1-(4-methylphenyl)-cyclopropane-1,2-
dicarboxylic acid (±)-13 using (-)-α-methyl-1-naphthylmethylamine (-)-15. The resolved diacid (+)-13 
is obtained as an enantiomerically pure sample. 
3.5.2 Synthesis via a bicyclic lactam 
Sorbera et al. presented in 2005 a variation of Epstein et al.’s method.14, 29 By reacting 
α-bromophenylacetate (16) with acrylonitrile (17), the cyanocyclopropane (18) is 
formed (Scheme 4). Upon reductive cyclisation this transforms into lactam 19. 
Reduction of this with Vitride yields the target compound 5c.  
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CN
16 17
NC O
O
N
H
ON
H
18
195c
Br
CO2Me
BH3
Vitride
NaH/Et2O
MeOH
Benzene
THF
 
Scheme 4: Synthesis of Bicifadine (5c) as published by Sorbera et al.14, 29 
3.5.3 Synthesis via an arylpyrroline using the Simmons-Smith 
reaction 
The same authors also reported a very short, direct method for synthesising these 
compounds.14, 29 The target compound 5c is made from the corresponding arylpyrrolin 
20 in a Simmons-Smith reaction (Scheme 5). Even though this looks like a short and 
useful synthesis, it is of little interest in this project as it does not give any control 
over the stereochemistry without the use of chiral additives. In addition, the necessary 
phenylpyrrolins must either be available or easily synthesised. 
 
Scheme 5: Synthesis of Bicifadine (5c) from methylphenylpyrroline (20)  published by Sorbera et al.14, 
29 
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3.5.4 Synthesis via a bicyclic lactone and lactam 
The published synthesis by Marrazzo et al. starts off from 1-aryl-3-
oxobicyclo[3.1.0]hexane-2-ones 2.27, 28 These compounds had already been 
synthesised with high ee in our research group, and seemed a good starting point for 
an asymmetric synthesis.31 This intermediate has the same carbon skeleton as the 
target compound. The lactone can be interconverted to the desired amine as outlined 
in Scheme 6. 
 
Scheme 6: The synthesis published by Marrazzo et al.27, 28 
From bicyclic lactone 2m cyclopropane carboxylate 21 is formed. Treatment with 
3.5.5 A one-pot synthesis via a cyclopropylaminoalcohol 
project.4 By 
sodium azide yields the azido intermediate 22 which cyclises upon reduction with 
sodium telluride. The lactam 19 is further reduced with borane to give the target 
compound 5m. An important drawback is the use of toxic tellurium.  
Xu et al. reported in 2006 a synthesis that looked very promising for our 
reacting aryl acetonitrile 1 with (+)-epichlorohydrine (23), hydroxynitrile 25 is formed 
via the intermediate 24 (Scheme 7). Reduction with borane yields the amine 26, which 
gives the target compound 5 by cyclodehydration, using thionyl chloride to form the 
chloride 27. As only the cis-diastereomer cis-27 can cyclise, the trans-diastereomer 
trans-27 can easily be removed after the last step. The overall synthesis is done as a 
- 16 - 
one-pot reaction. It involves several changes of solvents and counter ions at low 
temperature under inert atmosphere and therefore was not suited for making several 
analogues at small scale in a project with strict time limits.  
- 17 - 
 
Ar CN O Cl
Ar
-O
Cl
CN
HO
CN
Ar
HO
Ar
CN
HO
Ar
HO
Ar
NH2
NH2
Cl
Ar
Cl
Ar
NH2
NH2
N
Ar
R
1 (+)-23 cis-25
cis-26
24
cis-27
5
trans-25
trans-26trans-27
NaHMDS
THF
-15 ºC
6 h
BH3·Me2S
40 ºC, 4 h
SOCl2
i-PrOAcpH > 7.5
r.t., 2 h
NaOH (aq)
 
Scheme 7: The one-pot synthesis published by Xu et al.4 
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4 Synthesis and results 
After a short introduction of the planned synthetic route, this chapter presents how the 
synthesis was developed, showing the challenges of each step and how the final route 
was decided on. Then the results of the reactions are discussed. The last part of the 
chapter presents two alternative synthetic routes and the work conducted to pursue 
them. 
4.1 Background 
Previous work in our research group showed that the lactones 2 could be synthesised 
from substituted aryl acetonitriles 1 and epichlorohydrine (23) in three steps in a one-
pot synthesis (Scheme 8).4, 31  
 
Scheme 8: The synthesis of bicyclic lactones 2 from benzyl nitriles 1 and epichlorohydrine (23). 
The lactones 2 contain the same carbon skeleton as the target molecule, but there is an 
unwanted carbonyl functionality in the 2 position, as well as an oxygen atom at 
position 3, instead of the desired nitrogen atom. Normally lactones can only very 
slowly be reduced by sodium borohydride. However, previous work by Yamaguchi et 
al. shows that these lactones could be further reduced to cyclopropane diols 3;32 
thereby loosing their bicyclic moiety, which could then be reintroduced by ring-
closure of the diols with an amine as the nucleophile. This last step would also 
introduce the nitrogen atom at the correct position (Scheme 9). 
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Scheme 9: The proposed synthetic route to N-protected analogues 28 from the bicyclic lactones 2. 
Deprotection of 28 would yield the target compound. 
4.2 Synthesis via 2-oxo-1-aryl-3-oxabicyclo[3.1.0]hexanes 
4.2.1 Synthesis of 1-phenyl-3-oxabicyclo[3.1.0]hexane (2m) 
It was decided to complete the overall synthesis starting from unsubstituted phenyl 
acetonitrile (1m) and racemic epichlorohydrine (23) in order to explore the different 
steps and find suitable reaction conditions. 
The formation of 2-oxo-1-phenyl-3-oxa[3.1.0]bicyclohexane (2m) was completed 
following already known procedures using sodium amide in benzene to deprotonate 
phenyl acetonitrile (1m).31 Based on the procedure by Xu et al.,4 it seemed logical to 
try out the use of NaHMDS in THF, as this would remove the necessity of using toxic 
benzene. It was discovered that use of NaHMDS improved the yield of compound 2m 
from phenyl acetonitilie (1m) from 35% to 43%, and NaHMDS was consequently 
used as base from this stage on.  
The formation of the lactone 2m has been thoroughly investigated by Xu et al.4 The 
proposed reaction mechanism commences with the attack of the benzyl nitrile anion 
on epichlorohydrine (Scheme 10). The epoxide is reformed as chloride is expelled. 
The intermediate is then deprotonated, and subsequent intramolecular substitution 
gives the trisubstituted cyclopropane. 
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 Scheme 10: Proposed reaction mechanism for the formation of trisubstituted cyclopropanes. 
When the nitrile group is treated with hydroxide ion, it is hydrolysed to a carboxylic 
acid, and when this is treated with hydrochloric acid, the formation of the lactone is 
almost instantaneous. Only the cis-isomer where the hydroxyl group and the nitrile 
group are on the same side of the ring can form the lactone. This means that the 
reaction conditions should afford a high cis/trans ratio. In addition, this makes the 
separation of the two diastereomers easy, as this can be done after the cyclisation.  
The authors also show that the cis/trans ratio is very dependent on the counter ion of 
the base used, and that the use of sodiume as counter ion gives the highest cis/trans 
ratio.4 Some counter ions may lead to the formation of unwanted products. For 
instance, when Mg2+ is used, none of the wanted cyclopropane product is formed. 
Instead, a cyclobutane is formed, probably through the reaction mechanism outlined 
in Scheme 11.  
 
Scheme 11: Proposed reaction mechanism for the formation of trisubstituted cyclobutanes. 
4.2.2 Synthesis of 1-phenyl-1,2-cyclopropanedimethanol (3m) 
The reduction of the lactone 2m was achieved using sodium borohydride as reducing 
agent, and the cyclopropane diol 3m was isolated in more than 95% yield (Scheme 9, 
p. 20).32 
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4.2.3 Synthesis of 1-phenyl-3-(4-methoxybenzyl)-3-azabicyclo 
[3.1.0]hexane (4m) 
To complete the ring closure with the amine, it was believed necessary to introduce a 
better leaving group at both the hydroxyl groups. The mesyl group was chosen for its 
beneficial properties as a leaving group, as well as providing improved atom economy 
compared to tosyl, which was an obvious alternative. The mesyl groups were 
introduced using mesyl chloride in the presence of a suitable base, such as Hünig’s 
base, giving dimesylate 29m (Scheme 12). The product decomposed on silica and 
could not be purified by column chromatography, but was found to be of sufficient 
purity by 1H-NMR analysis of the crude reaction mixture, and it was decided to 
proceed without further purification.  
 
Scheme 12: The introduction of mesyl leaving groups. 
Different amines were considered as nucleophiles in the ring closure step. First 
allylamine (30) was tried, as a Bicifadine analogue with an allyl group attached to its 
nitrogen atom has shown interesting biological activity. Unfortunately, allylamine was 
not nucleophilic enough to yield the desired product 33 under the reaction conditions 
chosen (Scheme 13).  
 
Scheme 13: Ring closure with 4-methoxybenzyl amine 32. 
Next, benzyl amine (31) was tried, as the reaction could be run at higher temperature 
without the amine evaporating. This gave the desired product 34 in 19% isolated 
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yield. This was rather low, but no attempts to improve the reaction were done, as it 
was thought better to change to 4-metoxybenzyl amine (32, PMB), as several 
protocols for removing this protecting group are known. The reaction between 
mesylate 29m and 4-metoxybenzyl amine (32) gave the desired product 4m in 47% 
yield (Table 4). 
Table 4: Ring closure of 29 with different amines. 
Amine Reaction time Yielda Product 
Allylamine (30) > 24 h 0 % 33 
Benzylamine (31) > 24 h 19 % 34 
p-Methoxybenzylamine (32) 18 h 4m 47 % 
a. Isolated yield after flash chromatography. 
The isolated yield was lower than anticipated, and different parameters in the 
procedure were varied to see if the yield could be improved.  
First the reaction time was varied, but both shorter and longer reaction time gave less 
product. The base was changed from K2CO3 to Hünig’s base, but this only gave a 
small decrease in reaction yield (Table 5). 
Table 5: Different reaction conditions for the cyclisation of 29. 
Base Reaction time Yield of 4ma 
K2CO3 6 h 22 % 
K2CO3 18 h 47 % 
K2CO3 36 h 18 % 
Hünig’s base 18 h 40 % 
a. Isolated yield after flash chromatography. 
It was decided to try chloride as a leaving group instead of the mesylate. The 
cyclopropane diol 3m was treated with thionyl chloride (Scheme 14), but this did not 
yield the desired product 35m. Instead a complex mixture was obtained that was not 
analysed beyond 1H-NMR analysis of the crude product. 
CH2OH
Ar
HOH2C
SOCl2
3
CH2Cl
Ar
ClH2C
35
Pyridine
CH2Cl2, 50ºC   
Scheme 14: The reaction of cyclopropane diol 3 with thinoyl chloride. 
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It was decided that a yield of almost 50 % was good enough for this project, and the 
reaction was done using these reaction conditions throughout the rest of the project. 
4.2.4 Synthesis of 1-phenyl-3-azabicyclo[3.1.0]hexane (5m) 
The only step remaining was the removal of the PMP protecting group (Scheme 15).  
N
Ar
PMB
N
H
Ar
4 5  
Scheme 15: The deprotection of PMB-protected amine 4 to give the target compound 5. 
According to literature there are four frequently used ways to remove this protecting 
group.33 Attempted removal by hydrogenation in the presence of palladium on 
charcoal gave only starting material, as detected in 1H-NMR analysis of the crude 
reaction mixture.34 Oxidation with cerium ammonium nitrate was investigated, but no 
product was detected, and judging by 1H-NMR analysis of the crude reaction mixture, 
the starting material was not converted.35, 36 Then a procedure using α-chloroethyl 
chloroformate (ACE) was investigated. Following the procedure published by Yang et 
al.,37 the desired product 5m was synthesised in an excellent 99 % yield (Scheme 16).  
N
Ar
PMB
4
1. ACE, CH2Cl2, 0 ºC, 20 min
N
H
Ar
5
2. MeOH, reflux, 40 min ·HCl
 
Scheme 16: Removal of the PMB protecting group by ACE.37 
Yang et al. have also investigated the two other procedures, and their conclusion is 
exactly the same as ours; i.e. that with this type of compounds, it is not possible to 
remove the protecting group by either hydrogenation or oxidation.37 
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Table 6: The deprotection of compound 4 using different reagents. 
Yield of 5ma Reagent 
H2, Pd/C 0 % 
Cerium ammonium nitrate 0 % 
α-chloroethyl chloroformate 99 % 
a. Isolated yield. 
4.2.5 Conclusion 
This last step concluded the synthesis of the target compound 5m, and the complete 
reaction sequence is summarised in Scheme 17. 
Ph CN
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O O
Ph1. NaHMDS/THF, -15 ºC
2. NaOH, EtOH, reflux
3. HCl
1m 2m23
CH2OH
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Scheme 17: The final synthetic route to Bicifadine analogue 5m. 
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4.3 Synthesis of enantiomerically enriched Bicifadine 
analogues 
4.3.1 Introduction 
The focus was then turned to completing the synthesis starting from enantiomerically 
pure epichlorohydrine. The phenyl analogue 1m was again chosen as test compound, 
and the enantiomeric excess of the synthesis was measured for the lactone (B)-2m 
(Figure 6). There are two main reasons for analysis at this stage. The enantiomeric 
excess is measured early in the synthesis, so that the synthesis could be stopped if the 
enantiomeric excess was found to be to low for our purpose. If all the steps in the 
synthesis follow the presumed reaction mechanisms for these reactions, the 
configuration at the stereocentres is formed during the first step and not changed 
during the subsequent steps. 
O O
Ar
2
2h: Ar=3,4-dichlorophenyl
2m: Ar=Ph  
Figure 6: The two compounds used to test the asymmetric synthesis. 
The reaction was carried out using the same reaction conditions as stated for the 
synthesis of the racemic lactone. The lactone (B)-2m was isolated in 48% yield and 
87% ee The next analogue to be tested was lactone (B)-2h (Figure 6). The product 
was isolated in 43% yield and 98% ee The difference in ee between these compounds 
was found to be significant, so an explanation for this was sought.  
Starting from enantiomerically pure epichlorohydrine, one might expect the product to 
have the same enatiomeric purity. Unfortunately, the anion formed from the 
arylacetonitrile can attack epichlorohydrine at two different carbon atoms giving rise 
to the two different enantiomers (Scheme 18). In order to obtain the product in high 
enantiomeric excess, the reaction conditions must control the attack, so that one 
carbon atom is greatly preferred over the other. It does not matter which of the carbon 
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atoms is preferred; as both (R)- and (S)-epichlorohydrine are commercially available, 
both enantiomers of the product can be synthesised.  
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cis-25 trans-25  
Scheme 18: The two reaction mechanisms proposed by Xu et al. that will give different enantiomers of 
lactone 2.4 
Xu et al. showed that the attack can be controlled, and that three parameters are very 
important: The base, the counter ion of the base and the basisity of the arylacetonitrile 
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anions.4 Their work show that HMDS bases are best for this reaction, and that the 
enantiomeric excess increases with less basic arylacetonitrile anions, i.e. increasing 
with more electronegative substituents on the aromatic ring. The rational for this 
observation is complex, which is further underlined by the fact that this effect can be 
completely overridden by the effect of ion pairing with the counter ion of the base. To 
achieve this, the counter ion has to be changed during the reaction, and this procedure 
was found to be time consuming and the results difficult to reproduce. For our 
purpose, this synthesis appeared not to be a good choice, and it was decided to utilise 
the procedure from the test system (NaHMDS in THF) as long as this gave acceptable 
ee. 
4.3.2 Synthesis of 1-aryl-3-oxabicyclo[3.1.0]hexan-2-ones (2) 
The asymmetric synthesis using (+)- or (-)-epichlorohydrine was completed for 25 
compounds according to Scheme 19 in moderate to acceptable yields (36-68%) and 
good to excellent ee (79-99%) as shown in Table 7. One racemic mixture was also 
synthesised from racemic epichlorohydrin. 
 
Scheme 19: The synthesis of lactones 2. 
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Table 7: Yields and ee for the bicyclic lactones 2. 
Structure Yield ee 
(A)-2a 44 % 97 % 
 (B)-2a 31 % 99 % 
(A)-2b 46 % 90 % 
 (B)-2b 46 % 90 % 
(A)-2c 46 % 90 % 
 (B)-2c 37 % 89 % 
(A)-2d 57 % 97 % 
 (B)-2d 57 % 97 % 
(A)-2e 
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67 % 99 % 
 (B)-2e 68 % 99 % 
(A)-2f 27 % 92 % 
 (B)-2f 36 % 93 % 
(A)-2g 35 % 79 %a  
 (B)-2g 40 % 99 % 
(A)-2h 58 % 95 % 
 (B)-2h 43 % 98 % 
(A)-2i 37 % 98 % 
 (B)-2i 43 % 85 % 
(A)-2j 49 % 96 % 
 (B)-2j 62 % 95 % 
(A)-2k 49 % 93 % 
 (B)-2k 51 % 94 % 
(A)-2l 34 % 95 % 
 (B)-2l  86 % 
(A)-2m -b - 
(B)-2m 48 % 87 % 
 (±)-2m 43 % - 
a. The compound was not resynthesised due to lack of time. b. The compound was not synthesised due 
to lack of time. 
The difference in yields is most likely caused by different ratios between the different 
possible pathways showed in Scheme 18 (p. 27). As only cis-cyano alcohol cis-25 will 
give the desired product, any decrease in the rate of the pathway to this intermediate, 
will ultimately give less product. Both electronic and steric effects have been shown 
to influence the ratio between different pathways,4 but it is beyond the scope of this 
work to investigate this further. 
The difference in ee is thought to be a result of subtle electronic effects when 
changing the aryl group.4 The nucleophilisity of the carbanion formed by 
deprotonating the aryl acetonitrile 1 (Scheme 10, p. 21) decreases with more 
electronegative substituents on the aryl group. More nucleophilic anions tend to react 
less selectively, thus resulting in lower ee as described in Scheme 18 (p. 27). This 
theory does not explain all the differences in ee in Table 7 (p. 29), especially not 
differences between two enantiomers of the same analogue. Several explanations were 
considered, but no decisive conclusions were drawn. A number of bottles of 
epichlorohydrine have been used, and these have not been tested for optical purity. 
The temperature of the reaction, the rate of addition of the base and other reaction 
conditions probably influence ee of the product. Everything was done to have the 
same conditions in each reaction, but as each reaction was done only once, differences 
might have occurred, giving rise to a spread in ee values. 
4.3.3 Synthesis of 1-aryl-1,2-cyclopropanedimethanols (3) 
The syntheses of cyclopropane diols 3 from bicyclic lactones 2 were completed in 
moderate to excellent yields (74-99%) according to Table 8 (Scheme 20). 
 
Scheme 20: The synthesis of diols 3 from lactones 2. 
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Table 8: The yields in the formation of diols 3. 
Structure Yield 
(A)-3a 99 % 
 (B)-3a 99 % 
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(A)-3b 95 % 
 (B)-3b 97 % 
(A)-3c 94 % 
 (B)-3c 98 % 
(A)-3d 79 % 
 (B)-3d 80 % 
(A)-3e 94 % 
 
(B)-3e 99 % 
(A)-3f 99 %a 
 (B)-3f 98 % 
(A)-3g 67 % 
 (B)-3g 74 % 
(A)-3h 99 % 
 (B)-3h 97 % 
(A)-3m -b 
 (B)-3m 95 % 
a. The synthesis was completed after adding an extra equivalent of NaBH4. b. The compound was not 
synthesised due to lack of time. 
The synthesis of compound (B)-3m is reported in 100% yield under similar reaction 
conditions as those used in this project.32 It is therefore natural to seek explanations 
for the inferior results shown for some entries in Table 3. A significant improvement 
in the yield was noticed when using sodium borohydride from a newly purchased box. 
This might imply that the old one had started. The reduction of esters with sodium 
borohydride is generally very slow, and in some reactions the 1H-NMR of the crude 
product showed the presence of a small quantity of the lactone starting material 2. No 
attempt to purify the product was conducted, as it was shown in a test reaction that the 
starting material did not interfere in the next step. In addition the product was purified 
using flash chromatography after the next step, and this would remove unreacted 
lactone. 
In one instance the presence of starting material was detected before commencing the 
next reaction. The starting material 2 was then converted by redissolving the crude 
mixture and adding more reagent. This indicates that total conversion should be 
possible to achieve for all the compounds. 
4.3.4 Synthesis of 1-aryl-3-(4-methoxybenzyl)-3-azabicyclo[3.1.0] 
hexanes (4) 
The synthesis of 16 analogues of the N-protected bicyclic amine 4 was completed 
from the corresponding diols 3 according to Table 9 (Scheme 21). 
 
Scheme 21: The synthesis of the PMB-protected amines 4 from diols 3. 
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Table 9: The yields in the formation of N-protected bicyclic amines 4. 
Structure Yield 
(A)-4a 22 % 
 (B)-4a 26 % 
- 33 - 
(A)-4b 42 % 
 (B)-4b 52 % 
(A)-4c 45 % 
 (B)-4c 32 % 
(A)-4d 39 % 
 (B)-4d 33 % 
(A)-4e 25 % 
 
(B)-4e 19 % 
(A)-4f 58 % 
 (B)-4f 55 % 
(A)-4g 28 % 
 (B)-4g 34 % 
(A)-4h 76 % 
 (B)-4h 70 % 
(A)-4m -a 
 -b (B)-4m 
a. The compound was not synthesised due to lack of time. b. The starting material 3m was used in a 
reaction that did not give the desired product, and the reaction was not repeated due to lack of time. 
The yields in these reactions are much lower than anticipated. Yet they gave the 
product in large enough yields to complete the syntheses of the target compounds, so 
it was decided to keep the procedure unaltered, after trying to increase the yield as 
described in section 4.2.3 (pp. 22-24). As the yields are significantly different both 
between different analogues and between two enantiomers of the same analogue, an 
explanation was sought. Potassium carbonate was used from two different boxes 
during the project. The first was quite large particles that might have had a small 
surface area, thus working poorly as a heterogeneous base. The other was a very fine 
powder, which should work better as a heterogeneous base, but it is difficult to come 
to any conclusions.  
4.3.5 Synthesis of 1-aryl-3-azabicyclo[3.1.0]hexanes (5) 
The synthesis of the target molecules 5 was completed for 16 compounds as 8 
enantiomeric pairs in poor to good yields (20-72 %) according to Table 10 (Scheme 
22).37 
 
Scheme 22: The deprotection of compounds 4 to give the target compounds 5.37 
Table 10: The yields of the deprotected target compounds 5. 
Structure Yield 
(A)-5a 51 % 
 (B)-5a 32 % 
- 34 - 
(A)-5b 36 % 
 (B)-5b 27 % 
(A)-5c 72 % 
 (B)-5c 70 % 
(A)-5d 54 % 
 (B)-5d 45 % 
(A)-5e 32 % 
 
(B)-5e 20 % 
(A)-5f 44 % 
 (B)-5f 41 % 
(A)-5g 63 % 
 (B)-5g 63 % 
(A)-5h 70 % 
 (B)-5h 25 % 
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The purification of the products was achieved by recrystallisation from acetonitrile. 
This reaction is reported to yield the product quantitatively for a range of substrates.37 
When this is not the case for the analogues in this project, this is ascribed to the 
recrystallisation from acetonitrile. No starting material could be detected in 1H-NMR 
of the crude mixture, and there is no obvious reason why the procedure should give 
poorer results for our range of substrates than the ones already reported. Additionally, 
no better solvent for recrystallisation was found. As the product could easily be 
isolated as a crystalline white solid of excellent purity, other methods of purification 
were discarded. The yields are probably a better measurement of how well the 
recrystallisation was conducted than the actual chemistry in the reaction. The 
recrystallisation of the compounds proved difficult, especially for some analogues and 
this was linked to low yields. Experience with the recrystallisation procedure lead to 
higher yields for the analogues synthesised latest in the project. Anyhow, all the 
analogues were synthesised in large enough quantities for analysis and biological 
testing. 
4.3.6 X-ray crystallography 
To ensure that the absolute stereochemistry of the final compounds were in agreement 
with the literature and our beliefs, crystals were grown of compound (A)-5f. The 
crystal structure was solved, and the stereochemistry was shown to be in accordance 
with theory. An ORTEP drawing of the structure is shown in Figure 7. 
 Figure 7: ORTEP drawing of compound (A)-5f. 
The crystallographic data are included in the appendix. 
4.4 Other synthetic routes  
4.4.1 Synthesis of cyclopropanes by extrusion reactions 
A well known synthetic route to substituted cyclopropanes is by the extrusion of 
nitrogen gas from substituted 1-pyrazolines (Scheme 23).38  
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Scheme 23: A generalised scheme for the reaction of a substituted 1-pyrazoline to give a substituted 
cyclopropane.  
Quiclet-Sire and Zard reported in 2006 a reaction that showed an interesting way to 
form 1-pyrazolines.39 It was decided that a second route to the target compounds was 
worth pursuing. A retrosynthetic analysis of the target compound showed that it could 
be synthesised in few steps from commercially available starting materials (Scheme 
24). 
- 36 - 
N
H
Ar
Ar
N
N
Ar
H
N
O
Ar
Br
O
H2N
5 37
3839 40
N
N
N
Ts
Ar
Ts
H2N
36
 
Scheme 24: Retrosynthetic analysis of Bicifadine analogue 5 via a substituted 1-pyrazoline. 
The target compound 5 could most likely be synthesised from the 1-pyrazoline 36 
using standard reaction conditions for cyclopropanation by extrusion of nitrogen gas. 
The 1-pyrazoline 36 could be synthesised by the reaction proposed by Quiclet-Sire 
and Zard from the hydrazone 37.39 The hydrazone 37 should be possible to synthesise 
from ketone 38 by standard chemistry. The tosyl protecting group could be introduced 
at any time before the formation of the 1-pyrazolidine ring. Ketone 38 was to be 
synthesised from the commercially available 1-aryl-2-bromoethan-1-ones 39 and 
allylamine (40).  
Direct nucleophilic attack on the ketone 39 by allylamine (40) might be problematic 
as the highly nucleophilic amine probably would attack the ketone moiety. A few test 
reactions with different solvents and bases were conducted. These gave rise to 
complex mixtures that were not analysed beyond 1H-NMR analysis of the crude. The 
most probable reason why the desired product was not obtained, seemed to be exactly 
the predicted preference to attack the ketone. It was decided to protect the amine as 
carbamate 42 using Boc2O (41, Scheme 25).  
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 Scheme 25: The protection of allylamine (40) as a tert-butylcarbamate 42. 
This would considerably lessen the nucleophilisity of the amine and hopefully the size 
of the protecting group would help directing the attack at the primary, unhindered 
alkyl halide instead of the ketone. The test reaction revealed that this was not the case 
(Scheme 26).  
 
Scheme 26: Attempted synthesis of the tert-butylcarbamate protected intermediate 43. 
Judging by 1H-NMR analysis of the crude product, none of the desired product 43 was 
formed, and the complex mixture that was obtained was not analysed further. Other 
reaction conditions and other protecting groups were tried, but non of the desired 
product was formed. The results of these test reactions are summarised in Table 11. It 
is again reasonable to believe that the main product was formed by attack on the 
ketone.  
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Table 11: The results of the test reactions attempting to synthesise compound 43. 
Amine Solvent Base Conversion of 39a 
Allylamine 40 MeCN K2CO3 0 % 
Allylamine 40 MeOH K2CO3 0 % 
Allylamine 40 CH2Cl2 Hünig’s base 0 % 
Allylamine 40 Et2O/PhH - 0 % 
Boc-Allylamine 42 DMF K2CO3 0 % 
Ts-Allylamine THF KOtBu 0 % 
PMB-Allylamine MeCN K2CO3 0 % 
a. By TLC analysis. 
One possible way of overcoming this problem was to mask the ketone. The standard 
way of doing this is by transforming it into a cyclic ketal by reaction with ethylene 
glycol (44, Scheme 27). The product 45 was formed almost quantitatively using 
standard procedure.40  
 
Scheme 27: The protection of the ketone 39 as a cyclic ketal 45. 
It is known from the literature that N-H bonds will interfere with the formation of the 
1-pyrazoline ring.39 Seeing that the amine eventually would need to be protected 
anyway, it was decided to use the carbamate 42 for the substitution reaction with ketal 
45 (Scheme 28).  
 
Scheme 28: The synthesis of the tert-butylcarbamate protected ketal 46. 
The direct substitution at ambient temperature did not give the desired product 46. It 
is known that the nucleophilisity of carbamates are inferior compared to that of free 
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amines. One way around this problem is to use a strong base to deprotonate the 
carbamate. The anion of the carbamate is strongly nucleophilic. 
Sodium hydride, a standard base for this purpose, was chosen. The reaction was tried 
at ambient temperature subsequently in diethyl ether, THF and DMF as solvents. In 
all three reactions, only starting material could be recovered judging by TLC analysis 
and 1H-NMR analysis of the crude reaction even after prolonged reaction time (> 24 
h).  
4.4.2 Synthesis via a common intermediate 
So far, all the synthetic routes presented have had one common feature: To make a 
new analogue, the entire synthesis needs to be repeated using a different starting 
material to incorporate the desired substitution on the aryl group. One way of 
avoiding this is by parallel synthesis via a common intermediate. The differentiation 
of the analogues should be done as late as possible in the synthesis to reduce the 
number of steps required. A recent review showed a promising way of attaching the 
aryl group in the last step from a common intermediate, and the following synthetic 
route was envisioned (Scheme 29).41 
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Scheme 29: The proposed synthesis of Bicifadine analogues 5 via a common intermediate 52 or 53. 
Previous work in our group has shown that the reaction of dimethyl malonate (47) 
with p-ABSA gives the diazo compound 48.42 By slowly adding a solution of N,N-
bis(tert-butoxycarbonyl)allylamine (49) in dichloromethane to a refluxing solution of 
the diazo compound 48 and a rhodium catalyst in dichloromethane, cyclopropane 50 
is formed.43 Upon treatment with dilute acid it was envisioned that the carbamate 
protecting groups would be removed, and the esters hydrolysed. This would enable 
the cyclisation into a lactam. Decarboxylation would then yield lactam 51 which has 
the same carbon skeleton as the target compound, but is missing the aryl group.  
In lactam 51 there is only one hydrogen atom in α-position to the carbonyl. This could 
hopefully be used to introduce the desired boron functionality needed to attach the 
aryl group. One way is to deprotonate the lactam 51 with a lithium base (e.g. LDA). 
Transmetalation with a alkylborate (e.g. B(OMe)3) and in situ treatment with 
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potassium hydrogen difluoride gives the potassium organotrifluoroborate 52. The 
potassium organofluoroborates are known to be stable compounds under several 
reaction conditions, and their coupling reaction to arylbromides is reported for 
cyclopropanes in high yields.41  As shown earlier, the reduction from lactam 19 to 
amine 5 is possible using B2H6. Hopefully it would be possible to do this reduction 
from lactam 52 to amine 53 i.e. before the introduction of the aryl group, as this 
would keep the number of total steps for making several analogues to a minimum. 
Although much is known about potassium organotrifluoroborates, the reactions 
proposed here are not reported. This means for example that one or more of the 
suggested steps may require NH protection of the amide.  
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5 Further research 
5.1 Biological testing 
The 16 analogues synthesised in this project are sent to Lundbeck A/S in Copenhagen, 
Denmark for biological testing. The results were not available at the time of writing. 
The testing will show the compounds’ affinity for the reuptake transporters for 
serotonin, norepinephrine and dopamine. Hopefully, one or more of the compounds 
will show high affinity for one, two or all three transporters. The test results can then 
be used to compile SAR data for the analogues. This might be helpful in future 
syntheses of new analogues with even higher affinity. The SAR data can also be used 
in the search for selective antagonists for only one type of transporters. 
5.2 Future synthetic work 
One way of continuing this project is to complete the two proposed syntheses in 
chapter 4.4. The synthesis via the extrusion reaction (Chapter 4.4.1, pp. 36-40) is not 
yet well understood,39 and a suitable way of controlling stereochemistry in the product 
must be found. The synthesis via the trifluoroborate (Chapter 4.4.2, pp. 40-42) will, if 
completed, present an entirely new way of synthesising Bicifadine analogues. The 
common intermediate will shorten the time needed to make a series of analogues 
considerably.  
An alternative way of continuing the project is to synthesise more analogues using the 
established synthesis. Together with biological testing this will hopefully lead to a 
better understanding of the biological activity of Bicifadine analogues. 
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6 Conclusion 
The bicyclic lactones 2 were prepared with twelve different aromatic groups as both 
enantiomers. Starting from commercially available arylacetonitriles and 
epichlorohydrin, the bicyclic lactones 2 were isolated in moderate to acceptable yields 
with high to excellent enantiomeric excess. Both enantiomers of eight 1-aryl-3-
azabicyclo[3.1.0]hexane hydrochlorides 5 were synthesised in three steps from the 
corresponding bicyclic lactones 2. All analogues will be tested for their affinity to the 
serotonin, norepinephrine and dopamine transporters. 
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7 Experimental 
7.1 General 
Solvents used as reaction media were of the following qualities: Ethanol (96 %) and 
diethyl ether (Ph Eur) were used as delivered from Arcus and Den norske eterfabrikk, 
respectively; dry solvents were dried using the MB SPS-800 solvent purification 
system from MBraun or by standard procedures.44 Solvents used for extraction were 
of technical grade. Chemicals were used as delivered from Sigma-Aldrich, except six 
arylacetonitriles that were delivered from Lundbeck in Denmark. Epichlorohydrin 
was of the following purity: (R)-Epichlorohydrin 99 % (98 % ee), (S)-epichlorohydrin 
98 % (97 % ee). Argon (4.0) for working in inert atmosphere was used as delivered 
from AGA. 
Thin layer chromatography was done on 60 F254 silica coated aluminium plates from 
Merck. Flash chromatography was done on silica gel from SdS (60 A, 40-63 μm, 550 
m2/g, pH 7) and Merck (Silikagel 60, 0.40-0.63 mm, 480-540 m2/g, pH 6.5-7.5) either 
manually or with an Isco Inc. CombiFlash Companion with PeakTrak software (v. 
1.4.10). Ethyl acetate and hexane used as eluents were of technical grade. 
NMR spectra were recorded on a Bruker Avance DPX200 or DPX300 instrument at 
200 or 300 MHz for 1H-NMR and 50 or 75 MHz for 13C-NMR at 25 ºC. Chemical 
shift (δ) is given in ppm relative to the solvent CDCl3 (7.24 ppm for 1H-NMR, 77.0 
ppm for 13C-NMR), CD3OD (3.31 ppm for 1H-NMR, 49.05 ppm for 13C-NMR). 
Coupling constants are given in Hz. All 13C-NMR spectra are decoupled. Peak 
assignment in 1H- and 13C-NMR spectra is based on information from DEPT135, 
HMQC and COSY experiments as needed. Peaks due to solvents such as 
dichloromethane, ethyl acetate and water, are not included in the interpretation of 
NMR spectra. 
MS spectra are recorded on a VG Prospec sector instrument from Fissions 
Instruments at 70 eV (EI). HR-MS is recorded using perfluorokerosene (PFK) as 
reference. For electrospray (ESI) a Micromass Q-Tof-2 mass spectrometer was used. 
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Melting points are recorded using a Büchi B-545 melting point apparatus, and are 
uncorrected. 
Enantiomeric excess was measured using a SpectraSYSTEM P2000 pump with a 
SpectraSYSTEM UV3000 UV detector and either a chiralcel OD-H column or a 
chiralcel AS-H column from Daicel Chemical Industries ltd.  
Optical rotation was recorded using a Perkin Elmer Instruments 341 Polarimeter at 20 
ºC with a sodium lamp using a wavelength of 589 nm. Solvents for measuring optical 
rotation were of HPLC grade. Optical rotation is not reported for compounds that 
were not sufficiently pure. 
The X-ray crystallography data are recorded on a Siemens SMART CCD 
diffractometer.i 
All compounds 2-5 are made using the general procedure described at the beginning 
of each chapter. For the rest of the compounds, the procedure is given in each case. Rf 
values, NMR spectra and MS spectra were identical for enantiomers and are only 
reported once. Melting points are reported for one enantiomer only. 
Some of the compounds prepared in this project are already reported in the literature. 
References are given to published data. All data is according to literature unless 
otherwise stated. 
 
i The collection of X-ray crystallography data and structure solving was done by professor C. H. 
Gørbitz. 
7.2 1-Aryl-3-oxabicyclo[3.1.0]hexan-2-ones (2) 
General procedure 
Arylacetonitrile 1 (15.0 mmol, 1.0 eq.) and epichlorohydrin 23 (18.0 mmol, 1.2 eq.) 
were dissolved in THF (7.5 mL) under argon atmosphere and cooled to -20 ºC. 
NaHMDS (1.0 M in THF, 22.5 mL, 22.5 mmol, 1.5 eq.) was slowly added dropwise. 
After addition, the solution was stirred first at -20 ºC for 2 hours, then at ambient 
temperature for 1 hour. The solvents were evaporated in vacuo, and the residue 
dissolved in ethanol (30 mL) and aqueous KOH (1 M, 3 mL). The solution was 
refluxed for 18 hours and then cooled to 0 ºC. HCl (37 %, ~3 mL) was added (pH ~1), 
and the solution stirred at ambient temperature for 30 minutes. The mixture was 
concentrated in vacuo, and the residues were dissolved in ethyl acetate (30 mL), 
filtered, washed with brine (30 mL) and dried over MgSO4(s). The solution was 
concentrated in vacuo, and the compound was purified by flash chromatography on 
silica (0-30 % ethyl acetate in hexane). 
NMR analysis 
An in-depth NMR analysis is done on compound 2i (Fig. 8) for the bicyclic lactones 
2. 
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Figure 8: The structure of compound 2i. Relative stereochemistry is shown to demonstrate that Ha 
protons are on the same side of the plane as H5.  
The signals in the 1H-NMR spectrum are divided into three groups: The three signals 
on the cyclopropane ring; the four signals in the aromatic region; and the remaining 
two signals from the methylene group. The aromatic signals are easily identified, and 
the corresponding signals in the 13C-NMR spectrum are found using the HMQC 
spectrum.  Because of the adjacent oxygen atom, the H4 signals are shifted downfield 
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in the 1H-NMR spectrum, and the corresponding signal for C4 is found using the 
HMQC spectrum. Again using the HMQC spectrum, the 13C signal with two protons 
attached must be C6, and the remaining signal must be C5. The corresponding 1H 
signals are identified from the HMQC spectrum. There are three quaternary 13C 
signals, of which only two are distinguished: The C1 signal is from an aliphatic carbon 
atom and is expected to be found upfield. There is only one quaternary signal in this 
region when comparing the 13C-NMR spectrum and the DEPT spectrum. This is 
assigned C1. The C2 signal is expected to be found in the far downfield region of the 
13C-NMR spectrum. Only one signal is in the region for lactone signals, and this is 
assigned C2. 
Using Karplus’ rule and the geometry of the compound, it is possible to distinguish 
the two H4 signals and the two H6 signals. The COSY spectrum shows that only one 
of the H4 signals couple to the H5 signal. This is the H4b signal, as the dihedral angle 
H5-C5-C4-H4a is close to 90º, and no coupling is expected. The two H6 signals can be 
distinguished in a similar fashion. Using Karplus’ rule, both signals are expected to 
couple to H5, but with different coupling constants. The signal with the greatest 
coupling constant will be H6a, as the dihedral angle H5-C5-C6-H6a is close to 0º. The 
DEPT, HMQC and COSY spectra are included in the appendix. The proton coupling 
pattern between protons H4, H5 and H6 is summarised in Table 12. 
Table 12: The proton coupling pattern in compound 2i. 
δ (in ppm) Assignment JH-H Couples to 
4.7 Hz H6a 1.41 H6b 
4.7 Hz H5 
7.8 Hz H5 1.76 H6a 
4.7 Hz H6b 
7.8 Hz H6a 
4.7 Hz H6b 
2.39 H5 
4.7 Hz H4a 
4.38 H4b 9.2 Hz H4a 
9.2 Hz H4b 4.65 H4a 
4.7 Hz H5 
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1-(2-methylphenyl)-3-oxa-bicyclo[3.1.0]hexan-2-one (2a) 
 
Yield: 1.97 g (15.0 mmol) of 1a gave 1.25 g (6.64 mmol, 44%) of (A)-2a as a light 
yellow solid. 
Rf: 0.55 (40% ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 1.36 (t, 1H, J=4.7Hz, H6b), 1.66 (dd, 1H, J=7.8Hz, 
J=4.7Hz, H6a), 2.37 (s, 3H, H13), 2.38 (m, 1H, H5), 4.34 (d, 1H, J=9.4Hz, H4a), 4.54 
(dd, 1H, J=9.4Hz, J=4.7Hz, H4b), 7.13-7.26 (m, 4H, Ar-H). 
13C-NMR (75 MHz; CDCl3) δ 18.4 (C6), 19.6 (C13), 24.7 (C5), 31.9 (C1), 68.3 (C4), 
126.1 (Ar-CH), 128.6 (Ar-CH), 130.4 (Ar-CH x 2), 132.5 (Ar-C), 138.9 (Ar-C), 175.9 
(C2). 
MS (EI) m/z (relative intensity): 188 (M+, 79%), 160 (78), 143 (79), 129 (99), 128 
(100). 
HR-MS: 188.0830; Calculated value for C12H12O2: 188.0837 (3.8 ppm). 
Melting point: (B)-2a: 97-99 ºC (from ethyl acetate: hexane). 
(A)-2a: 
Ee: 97 % (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 28 min). [ ]20Dα : -7.3º (c 0.19, chloroform). 
(B)-2a: 
Ee: 99 % (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 27 min). [ ]20Dα : +8.9º (c 0.19, chloroform). 
Compound 2a is known in the literature, but only as (1S,5R).45 
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 Spectrum 1: 1H-NMR spectrum of compound 2a. 
 
Spectrum 2: 13C-NMR spectrum of compound 2a. 
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1-(3-methylphenyl)-3-oxa-bicyclo[3.1.0]hexan-2-one (2b) 
 
Yield: 1.97 g (15.0 mmol) of 1b gave 1.29 g (6.83 mmol, 46%) of (A)-2b as a light 
yellow oil. 
Rf: 0.59 (40% ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 1.32 (t, 1H, J=4.7Hz, H6b), 1.62 (dd, 1H, J=7.8Hz, 
J=4.7Hz, H6a), 2.34 (s, 3H, H13), 2.51 (td, 1H, J=7.8Hz, J=4.7Hz, H5), 4.27 (d, 1H, 
J=9.2Hz, H4a), 4.44 (dd, 1H, J=9.2Hz, J=4.7Hz, H4b), 7.08-7.25 (m, 4H, Ar-H). 
13C-NMR (75 MHz; CDCl3) δ 19.9 (C6), 21.4 (C13), 25.0 (C5), 31.7 (C1), 68.1 (C4), 
125.3 (Ar-CH), 128.5 (Ar-CH x 2), 129.2 (Ar-CH), 134.0 (Ar-C), 138.3 (Ar-C), 176.1 
(C2). 
MS (EI) m/z (relative intensity): 188 (M+, 100%), 158 (35), 143 (15), 129 (55), 115 
(40). 
HR-MS: 188.0844; Calculated value for C12H12O2: 188.0837 (-3.7 ppm). 
(A)-2b: 
Ee: 90 % (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 20 min). [ ]20Dα : +70.4º (c 0.25, chloroform). 
(B)-2b: 
Ee: 90 % (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 23 min). [ ]20Dα : -25.2 (c 0.25, chloroform). 
Compound 2b is known in the literature, but only as (1S,5R).45 
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 Spectrum 3: 1H-NMR spectrum of compound 2b. 
 
Spectrum 4: 13C-NMR spectrum of compound 2b. 
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1-(4-methylphenyl)-3-oxa-bicyclo[3.1.0]hexan-2-one (2c) 
 
Yield: 1.97 g (15.0 mmol) of 1c gave 1.29 g (6.83 mmol, 46%) of (A)-2c as a white 
solid. 
Rf: 0.26 (20% ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 1.31 (t, 1H, J=4.7Hz, H6b), 1.60 (dd, 1H, J=7.8Hz, 
J=4.7Hz, H6a), 2.32 (s, 3H, H11), 2.49 (m, 1H, H5), 4.26 (d, 1H, J=9.2Hz, H4a), 4.44 
(dd, 1H, J=9.2Hz, J=4.7Hz, H4b), 7.14 (d, 2H, J=7.9Hz, Ar-H),  7.29 (m, 2H, Ar-H). 
13C-NMR (75 MHz; CDCl3) δ 19.9 (C6), 21.1 (C11), 25.0 (C5), 31.5 (C1), 68.1 (C4), 
128.3 (Ar-CH), 129.3 (Ar-CH), 131.0 (Ar-C), 137.5 (Ar-C), 176.2 (C2). 
MS (EI) m/z (relative intensity): 188 (M+, 100%), 158 (34), 143 (12), 129 (53). 
HR-MS: 188.0839; Calculated value for C12H12O2: 188.0837 (-1.1 ppm). 
Melting point: (B)-2c: 43-46  ºC (from ethyl acetate:hexane). 
(A)-2c: 
Ee: 90 % (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 22 min). [ ]20Dα : +56.4º (c 0.28, chloroform). 
(B)-2c: 
Ee: 89 % (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 24 min). [ ]20Dα : -69.6º (c 0.23, chloroform). 
Compound 2c is known in the literature.4, 45, 46 
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 Spectrum 5: 1H-NMR spectrum of compound 2c. 
 
Spectrum 6: 13C-NMR spectrum of compound 2c. 
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1-(2-fluorophenyl)-3-oxa-bicyclo[3.1.0]hexan-2-one (2d) 
 
Yield: 2.03 g (15.0 mmol) of 1d gave 1.63 g (8.50 mmol, 57%) of (B)-2d as a white 
solid. 
Rf: 0.52 (40% ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 1.32 (t, 1H, J=4.7Hz, H6b), 1.68 (dd, 1H, J=7.8Hz, 
J=4.7Hz, H6a), 2.43 (td, 1H, J=7.8Hz, J=4.7Hz, H5), 4.29 (d, 1H, J=9.3Hz, H4a), 4.51 
(dd, 1H, J=9.3Hz, J=4.7Hz, H4b), 7.01-7.14 (m, 2H, Ar-H), 7.26-7.37 (m, 2H, Ar-H). 
13C-NMR (75 MHz; CDCl3) δ 17.0 (C6), 24.5 (d, J=1.6Hz, C5), 27.9 (d, J=2.0Hz, 
C1), 68.3 (C4), 115.5 (d, J=21.1Hz, Ar-CH), 121.6 (d, J=14.3Hz, C7), 124.2 (d, 
J=3.7Hz, Ar-CH), 130.1 (d, J=8.3Hz, Ar-CH), 131.5 (d, J=3.1Hz, Ar-CH), 162.1 (d, 
J=248.2Hz, C8), 175.5 (C2). 
MS (EI) m/z (relative intensity): 192 (M+, 100%), 162 (45), 147 (34), 133 (75). 
HR-MS: 192.0581; Calculated value for C11H9FO2: 192.0587 (2.7 ppm). 
Melting point: (A)-2d: 76-78 ºC (from ethyl acetate:hexane). 
(A)-2d: 
Ee: 97 % (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 25 min). [ ]20Dα : +18.1º (c 0.26, chloroform). 
(B)-2d: 
Ee: 97 % (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 27 min). [ ]20Dα : -21.0º (c 0.21, chloroform). 
Compound 2d is known in the literature, but only as (1S,5R).45 
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 Spectrum 7: 1H-NMR spectrum of compound 2d. 
 
Spectrum 8: 13C-NMR spectrum of compound 2d. 
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1-(3-fluorophenyl)-3-oxa-bicyclo[3.1.0]hexan-2-one (2e) 
 
Yield: 2.03 g (15.0 mmol) of 1e gave 1.97 g (10.26 mmol, 68%) of (B)-2e as a yellow 
solid. 
Rf: 0.53 (40% ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 1.38 (t, 1H, J=4.7Hz, H6b), 1.62 (dd, 1H, J=7.8Hz, 
J=4.7Hz, H6a), 2.56 (dtd, 1H, J=7.9Hz, J=4.7Hz, J=0.5Hz, H5), 4.27 (d, 1H, 
J=9.3Hz, H4a), 4.44 (dd, 1H, J=9.3Hz, J=4.7Hz, H4b), 6.93-7.00 (m, 1H, Ar-H), 7.15-
7.18 (m, 2H, Ar-H), 7.26-7.33 (m, 1H, Ar-H). 
13C-NMR (75 MHz; CDCl3) δ 20.7 (C6), 25.4 (d, C5), 31.2 (d, J=2.4Hz, C1), 67.9 
(C4), 114.6 (d, J=21.0Hz, Ar-CH), 115.3 (d, J=22.6Hz, Ar-CH), 123.6 (d, J=2.9Hz, 
Ar-CH), 130.1 (d, J=8.5Hz, Ar-CH), 136.6 (d, J=7.9Hz, C7), 162.8 (d, J=246.4Hz, 
C9), 175.3 (C2). 
MS (EI) m/z (relative intensity): 192 (M+, 100%), 162 (49), 147 (28), 133 (68). 
HR-MS: 192.0584; Calculated value for C11H9FO2: 192.0587 (0.9 ppm). 
Melting point: (B)-2e: 75-76 ºC (from ethyl acetate:hexane). 
(A)-2e: 
Ee: 99% (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 25 min). [ ]20Dα : +84.1º (c 0.22, chloroform). 
(B)-2e: 
Ee: 99% (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 26 min). [ ]20Dα : -84.3º (c 0.21, chloroform). 
Compound 2e is known in the literature, but only as (1S,5R).45, 47 
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 Spectrum 9: 1H-NMR spectrum of compound 2e. 
 
Spectrum 10: 13C-NMR spectrum of compound 2e. 
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1-(4-fluorophenyl)-3-oxa-bicyclo[3.1.0]hexan-2-one (2f) 
 
Yield: 2.03 g (15.0 mmol) of 1f gave 1.04 g (5.41 mmol, 36%) of (B)-2f as a yellow 
oil. 
Rf: 0.46 (40% ethyl acetate in hexane) 
1H-NMR (300 MHz; CDCl3) δ 1.30 (t, 1H, J=4.7Hz, H6b), 1.54 (dd, 1H, J=7.8Hz, 
J=4.7Hz, H6a), 2.51 (dtd, 1H, J=7.8Hz, J=4.7Hz, J=0.4Hz, H5), 4.22 (d, 1H, 
J=9.3Hz, H4a), 4.40 (dd, 1H, J=9.3Hz, J=4.6Hz, H4b), 6.94-7.02 (m, 2H, Ar-H), 7.32-
7.38 (m, 2H, Ar-H). 
13C-NMR (75 MHz; CDCl3) δ 20.0 (C6), 24.8 (C5), 31.1 (C1), 68.0 (C4), 115.3 (d, 
J=21.5Hz, Ar-CH), 129.8 (d, J=3.2Hz, Ar-CH), 130.1 (d, J=8.2Hz, Ar-CH), 162.0 (d, 
J=245.1Hz, C9), 175.9 (C2). 
MS (EI) m/z (relative intensity): 192 (M+, 100%), 162 (45), 147 (33), 133 (74). 
HR-MS: 192.0583; Calculated value for C11H9FO2: 192.0587 (1.7 ppm). 
(A)-2f: 
Ee: 92% (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 25 min). [ ]20Dα : +51.2º (c 0.25, chloroform). 
(B)-2f: 
Ee: 93% (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 28 min). [ ]20Dα : -59.5º (c 0.21, chloroform). 
Compound 2f is known in the literature.31 
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 Spectrum 11: 1H-NMR spectrum of compound 2f. 
 
Spectrum 12: 13C-NMR spectrum of compound 2f. 
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1-(4-methoxyphenyl)-3-oxa-bicyclo[3.1.0]hexan-2-one (2g) 
 
Yield: 2.21 g (15.0 mmol) of 1g gave 1.22 g (5.98 mmol, 40%) of (B)-2g as a white 
solid. 
Rf: 0.26 (20% ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 1.30 (t, 1H, J=4.7Hz, H6b), 1.59 (dd, 1H, J=7.8Hz, 
J=4.7Hz, H6a), 2.47 (dtd, 1H, J=7.9Hz, J=4.7Hz, J=0.5Hz, H5), 3.78 (s, H, H11), 
4.25 (d, 1H, J=9.2Hz, H4a), 4.44 (dd, 1H, J=9.2Hz, J=4.7Hz, H4b), 6.82-6.90 (m, 2H, 
Ar-H), 7.28-7.35 (m, 2H, Ar-H). 
13C-NMR (75 MHz; CDCl3) δ 19.8 (C6), 24.8 (C5), 31.3 (C1), 55.3 (C11), 68.1 (C4), 
114.0 (Ar-CH), 126.0 (Ar-C), 129.7 (Ar-CH), 159.1 (C10), 176.4 (C2). 
MS (EI) m/z (relative intensity): 204 (M+, 100%), 174 (14), 159 (19), 147 (34), 146 
(31), 133 (22). 
HR-MS: 204.0790; Calculated value for C12H12O3: 204.0786 (-1.6 ppm). 
Melting point: (B)-2g: 111-112 ºC (from ethyl acetate:hexane). 
(A)-2g: 
Ee: 79% (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 32 min). [ ]20Dα : +52.2º (c 0.23, chloroform). 
(B)-2g: 
Ee: 99% (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 41 min). [ ]20Dα : -63.0º (c 0.20, chloroform). 
Compound 2g is known in the literature.31
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 Spectrum 13: 1H-NMR spectrum of compound 2g. 
Spectrum 14: 13C-NMR spectrum of compound 2g. 
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1-(3,4-dichlorophenyl)-3-oxa-bicyclo[3.1.0]hexan-2-one (2h) 
 
Yield: 2.79 g (15.0 mmol) of 1h gave 1.57 g (6.45 mmol, 43%) of (B)-2h as a brown 
solid. 
Rf: 0.47 (40% ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 1.43 (t, 1H, J = 4.7 Hz, H6b), 1.63 (dd, 1H, J=7.8Hz, 
J=4.7Hz, H6a), 2.61 (td, 1H, J=7.8Hz, J=4.7Hz, H5), 4.31 (d, 1H, J=9.3Hz, H4a), 4.48 
(dd, 1H, J=9.3Hz, J=4.7Hz, H4b), 7.30 (dd, 1H, J=8.4Hz, J=2.1Hz, Ar-H), 7.43 (d, 
1H, J=8.4Hz, Ar-H), 7.54 (d, 1H, J=2.1Hz, Ar-H). 
13C-NMR (75 MHz; CDCl3) δ 20.7 (C6), 25.2 (C5), 30.8 (C1), 67.9 (C4), 127.5 (Ar-
CH), 130.1 (Ar-CH), 130.5 (Ar-CH), 131.9 (Ar-C), 132.6 (Ar-C), 134.4 (Ar-CH), 
175.0 (C2). 
MS (EI) m/z (relative intensity): 242/244/246 (M+, 100%/65/11), 212/214/216 
(59/43/10), 163 (40), 149 (57), 128 (34). 
HR-MS: 241.9894; Calculated value for C11H8Cl2O2: 241.9901 (2.9 ppm). 
Melting point: (B)-2h: 97-99 ºC (from ethyl acetate:hexane). 
(A)-2h: 
Ee: 95 % (AS-H, 10% isopropanol in hexane, 1mL/min, Rt: 55 min). 
(B)-2h: 
Ee: 98 % (AS-H, 10 % isopropanol in hexane, 1 mL/min, Rt: 50 min). [ ]20Dα : -66.4º (c 0.22, chloroform). 
Compound 2h is known in the literature.31 
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 Spectrum 15: 1H-NMR spectrum of compound 2h. 
 
Spectrum 16: 13C-NMR spectrum of compound 2h. 
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1-(2-chlorophenyl)-3-oxa-bicyclo[3.1.0]hexan-2-one (2i) 
 
Yield: 2.27 g (15.0 mmol) of 1i gave 1.16 g (5.58 mmol, 37%) of (A)-2i as a white 
solid. 
Rf: 0.52 (40% ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 1.41 (t, 1H, J = 4.9 Hz, H6b), 1.76 (dd, 1H, J=7.8Hz, 
J=5.1Hz, H6a), 2.39 (td, 1H, J=7.9Hz, J=4.6Hz, H5), 4.38 (d, 1H, J=9.2Hz, H4a), 4.65 
(dd, 1H, J=9.2Hz, J=4.6Hz, H4b), 7.17-7.61 (m, 4H, Ar-H). 
13C-NMR (75 MHz; CDCl3) δ 17.3 (C6), 25.1 (C5), 32.2 (C1), 68.4 (C4), 127.1 (Ar-
CH), 129.5 (Ar-CH), 129.8 (Ar-CH), 132.1 (Ar-CH), 132.5 (Ar-C), 136.2 (Ar-CH), 
175.3 (C2). 
MS (EI) m/z (relative intensity): 208/210 (M+, 50%/16), 173 (100), 145 (26), 129 
(44), 115 (39). 
HR-MS: 208.0295; Calculated value for C11H9ClO2: 208.0291 (-2.1 ppm). 
Melting point: A-2i: 150-151 ºC (from ethyl acetate:hexane). 
(A)-2i: 
Ee: 98 % (AS-H, 10% isopropanol in hexane, 1mL/min, Rt: 49 min). [ ]20Dα : -12.0º (c 0.20, chloroform). 
(B)-2i: 
Ee: 85 % (AS-H, 10% isopropanol in hexane, 1mL/min, Rt: 66 min). [ ]20Dα : +13.0 (c 0.20, chloroform). 
Compound 2i is known in the literature, but only as (1R,5S) and the racemic mixture.4, 
46
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 Spectrum 17: 1H-NMR spectrum of compound 2i. 
 
Spectrum 18: 13C-NMR spectrum of compound 2i. 
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1-(3-chlorophenyl)-3-oxa-bicyclo[3.1.0]hexan-2-one (2j) 
 
Yield: 2.27 g (15.0 mmol) of 1j gave 1.93 g (9.23 mmol, 62%) of (B)-2j as a pale 
yellow oil. 
 Rf: 0.56 (40% ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 1.42 (t, 1H, J = 4.7 Hz, H6b), 1.65 (dd, 1H, J=7.8Hz, 
J=4.7Hz, H6a), 2.60 (td, 1H, J=7.8Hz, J=4.7Hz, H5), 4.32 (d, 1H, J=9.3Hz, H4a), 4.49 
(dd, 1H, J=9.3Hz, J=4.7Hz, H4b), 7.26-7.39 (m, 3H, Ar-H), 7.42-7.45 (m, 1H, Ar-H). 
13C-NMR (75 MHz; CDCl3) δ 20.5 (C6), 25.2 (C5), 31.3 (C1), 68.0 (C4), 126.4 (Ar-
CH), 127.9 (Ar-CH), 128.3 (Ar-CH), 129.9 (Ar-CH), 134.4 (Ar-C), 136.1 (Ar-C), 
175.3 (C2). 
MS (EI) m/z (relative intensity): 208/210 (M+, 100%/34), 178/180 (56/24), 151 (23), 
129 (56), 115 (67). 
HR-MS: 208.0290; Calculated value for C11H9ClO2: 208.0291 (0.4 ppm). 
(A)-2j: 
Ee: 96% (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 26 min). [ ]20Dα : +73.9º (c 0.23, chloroform). 
(B)-2j: 
Ee: 95% (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 27 min). [ ]20Dα : -69.0º (c 0.29, chloroform). 
Compound 2j is known in the literature.31 
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 Spectrum 19: 1H-NMR spectrum of compound 2j. 
 
Spectrum 20: 13C-NMR spectrum of compound 2j. 
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1-(4-chlorophenyl)-3-oxa-bicyclo[3.1.0]hexan-2-one (2k) 
 
Yield: 2.27 g (15.0 mmol) of 1k gave 1.61 g (7.72 mmol, 51%) of (B)-2k as a pale 
yellow oil. 
Rf: 0.55 (40% ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 1.37 (t, 1H, J=4.7 Hz, H6b), 1.58 (dd, 1H, J=7.8Hz, 
J=4.7Hz, H6a), 2.54 (td, 1H, J=7.8Hz, J=4.7Hz, H5), 4.27 (d, 1H, J=9.3Hz, H4a), 4.44 
(dd, 1H, J=9.3Hz, J=4.6Hz, H4b), 7.21-7.52 (m, 4H, Ar-H). 
13C-NMR (75 MHz; CDCl3) δ 20.4 (C6), 25.1 (C5), 31.1 (C1), 68.0 (C4), 128.8 (Ar-
CH), 129.6 (Ar-CH), 132.6 (Ar-CH), 133.6 (Ar-C), 175.5 (C2). 
MS (EI) m/z (relative intensity): 208/210 (M+, 100%/33), 178/180 (54/22), 151 (30), 
129 (52), 115 (67). 
HR-MS: 208.0298; Calculated value for C11H9ClO2: 208.0291 (0.9 ppm). 
(A)-2k: 
Ee: 93 % (AS-H, 10% isopropanol in hexane, 1mL/min, Rt: 43 min). [ ]20Dα : +66.1º (c 0.33, chloroform). 
(B)-2k: 
Ee: 94 % (AS-H, 10% isopropanol in hexane, 1mL/min, Rt: 47 min). [ ]20Dα : -65.3º (c 0.30, chloroform). 
Compound 2k is known in the literature.31 
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 Spectrum 21: 1H-NMR spectrum of compound 2k. 
 
Spectrum 22: 13C-NMR spectrum of compound 2k. 
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1-(Naphtalen-1-yl)-3-oxa-bicyclo[3.1.0]hexan-2-one (2l) 
 
Yield: 2.51 g (15.0 mmol) of 1l gave 1.13 g (5.05 mmol, 34%) of (A)-2l as a white 
solid. 
Rf: 0.57 (40% ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 1.53 (t, 1H, J = 4.7Hz, H6b), 1.77 (dd, 1H, J=7.8Hz, 
J=4.7Hz, H6a), 2.55 (td, 1H, J=7.8Hz, J=4.7Hz, H5), 4.45 (d, 1H, J=9.5Hz, H4a), 4.74 
(dd, 1H, J=9.5Hz, J=4.7Hz, H4b), 7.30-7.68 (m, 4H, Ar-H), 7.80-7.90 (m, 2H, Ar-H), 
7.93-7.99 (m, 1H, Ar-H). 
13C-NMR (75 MHz; CDCl3) δ 18.7 (C6), 24.8 (C5), 31.3 (C1), 68.4 (C4), 124.0 (Ar-
CH), 125.2 (Ar-CH), 126.1 (Ar-CH), 126.7 (Ar-CH), 128.5 (Ar-CH), 128.9 (Ar-CH), 
129.3 (Ar-CH), 130.5 (Ar-C), 132.7 (Ar-C), 133.9 (Ar-C), 176.0 (C2). 
Melting point: (A)-2l: 144-146 ºC (from ethyl acetate:hexane). 
(A)-2l: 
Ee: 95 % (OD-H, 10% isopropanol in hexane, 1mL/min, Rt: 46 min). [ ]20Dα : -66.4º (c 0.25 in chloroform). 
(B)-2l: 
Ee: 86 % (OD-H, 10 % isopropanol in hexane, 1 mL/min, Rt: 64 min). [ ]20Dα : +71.4º (c 0.22 in chloroform). 
Compound 2l is known in the literature.31 
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 Spectrum 23: 1H-NMR spectrum of compound 2l. 
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Spectrum 24: 13C-NMR spectrum of compound 2l. 
7.3 1-Aryl-1,2-cyclopropanedimethanols (3) 
General procedure 
Lactone 2 (1 eq.) was dissolved in THF/MeOH (10:1, 3.5 mL/mmol of compound 2) 
and cooled to 0 ºC. NaBH4 (3 eq.) was added in one portion, and the solution stirred at 
0 ºC until no more gas evolved. The reaction mixture was then stirred at ambient 
temperature for 18 hours. The mixture was concentrated in vacuo, and the residue 
dissolved in ethyl acetate (80 mL). The solution was washed with HCl (1 M, 2 x 40 
mL) and dried over MgSO4(s). The solvent was evaporated in vacuo to give the 
desired product 3. 
NMR analysis 
An in-depth NMR analysis is done on compound 3d (Fig. 9) for the cyclopropane 
diols 3. 
 
Figure 9: The structure of compound 3d.  
The protons in the 1H-NMR spectrum are divided into four groups: the four aromatic 
protons, the three protons on the cyclopropane, the two protons of the OH-groups and 
the remaining methylene groups. The aromatic signals are easily identified and the 
corresponding signals in the 13C-NMR spectrum found in the HMQC spectrum. The 
signal from the OH-groups are identified as a singlet. The three quaternary carbon 
atoms are found by comparing the 13C-NMR spectrum and the DEPT spectrum. The 
aliphatic C1 signal is easily identified in the upfield region, and the other two signals 
are distinguished by their coupling to the fluorine atom (This is not done for 
analogues not containing fluorine). The four signals from H4 and H5 are found 
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downfield because of the adjacent oxygen atoms. They are distinguished by the 
coupling between H5 and H2, whereas the H4 signals does not show this type of 
coupling. The corresponding C4 and C5 signals in the 13C-NMR are found using the 
HMQC spectrum. Because of the rotation about the C1-C4 and C2-C5 bonds, the H4 
and H5 signals are not further distinguished. The distinction between H3a and H3b is 
done by comparing the coupling constants to H2. H3a is expected to have the greatest 
coupling constant based on Karplus’ rule. The DEPT, HMQC and COSY spectra are 
included in the appendix. The proton coupling pattern between protons H2, H3 and H5 
is summarised in Table 13. 
Table 13: The proton coupling pattern in compound 3d. 
δ (in ppm) Assignment JH-H Couples to 
5.5 Hz H3a 0.81 H3b 
5.5 Hz H2 
8.6 Hz H2 1.02 H3a 
5.5 Hz H3b 
11.5 Hz H5 
8.6 Hz H3a 
5.5 Hz H3b 
1.64 H2 
5.5 Hz H5’ 
11.5 Hz H2 3.38 H5 
11.5 Hz H5’ 
11.5 H5 4.15 H5’ 
5.5 H2 
 
 
1-(2-methylphenyl)-1,2-cyclopropanedimethanol (3a) 
 
Yield: 1.22 g (6.50 mmol) of (A)-2a gave 1.23 g (6.41 mmol, 99%) of (A)-3a as a 
pale oil. 
Rf: 0.49 (50 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.88 (t, 1H, J=5.1Hz, H3b), 1.02 (dd, 1H, J=8.6Hz, 
J=5.1Hz, H3a), 1.73 (m, 1H, H2), 2.43 (s, 3H, H12), 2.84 (s, 2H, OH), 3.45 (t, 1H, 
J=11.5Hz, H5), 3.53 (d, 1H, J=12.0Hz, H4), 4.10 (d, 1H, J=12.0Hz, H4), 4.21 (dd, 1H, 
J=11.5Hz, J=5.4Hz, H5), 7.14-7.23 (m, 3H, Ar), 7.37-7.43 (m, 1H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 17.2 (C3), 19.1 (C12), 25.6 (C2), 31.4 (C1), 63.6 (C5), 
66.6 (C4), 125.8 (Ar-CH), 127.1 (Ar-CH), 130.5 (Ar-CH), 132.0 (Ar-CH), 137.5 (Ar-
C), 140.8 (Ar-C). 
(A)-3a: 
[ ]20Dα : +41.9º (c 0.21, chloroform). 
(B)-3a: 
[ ]20Dα : -46.3º (c 0.19, chloroform). 
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 Spectrum 25: 1H-NMR spectrum of compound 3a. 
Spectrum 26: 13C-NMR spectrum of compound 3a. 
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1-(2-methylphenyl)-1,2-cyclopropanedimethanol (3b) 
 
Yield: 1.22 g (6.50 mmol) of (B)-2b gave 1.21 g (6.29 mmol, 97%) of (B)-3b as a 
pale oil. 
Rf: 0.50 (50 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.73 (t, 1H, J=5.2Hz, H3b), 1.04 (dd, 1H, J=8.5Hz, 
J=5.0Hz, H3a), 1.66 (tt, 1H, J=10.9Hz, J=5.5Hz, H2), 2.33 (s, 3H, H12), 2.76 (s, 2H, 
OH), 3.39 (t, 1H, J=11.4Hz, H5), 3.52 (d, 1H, J=11.9Hz, H4), 4.15 (m, 2H, H4 H5), 
7.00-7.05 (m, 1H, Ar), 7.11-7.22 (m, 3H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 16.8 (C3), 21.4 (C12), 25.7 (C2), 32.3 (C1), 63.6 (C5), 
67.6 (C4), 126.3 (Ar-CH), 127.5 (Ar-CH), 128.3 (Ar-CH), 130.0 (Ar-CH), 138.0 (Ar-
C), 143.7 (Ar-C). 
(A)-3b: 
[ ]20Dα : +41.9º (c 0.21, chloroform). 
(B)-3b: 
[ ]20Dα : -46.3º (c 0.19, chloroform). 
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 Spectrum 27: 1H-NMR spectrum of compound 3b. 
Spectrum 28: 13C-NMR spectrum of compound 3b. 
- 81 - 
1-(4-methylphenyl)-1,2-cyclopropanedimethanol (3c) 
 
Yield: 1.02 g (5.44 mmol) of (B)-2c gave 1.02 g (5.31 mmol, 98%) of (B)-3c as a 
pale oil. 
Rf: 0.49 (50 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.72 (t, 1H, J=5.3Hz, H3b), 1.02 (dd, 1H, J=8.6Hz, 
J=5.3Hz, H3a), 1.64 (m, 1H, H2), 2.31 (s, 3H, H10), 2.86 (s, 2H, OH), 3.37 (t, 1H, 
J=11.5Hz, H5), 3.51 (d, 1H, J=11.9Hz, H4), 4.06-4.19 (m, 2H,  H4 H5), 7.08-7.14 (m, 
2H, Ar), 7.24-7.30 (m, 2H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 16.8 (C3), 21.0 (C10), 25.7 (C2), 31.9 (C1), 63.5 (C5), 
67.6 (C4), 129.1 (Ar-CH), 129.2 (Ar-CH), 136.3 (Ar-C), 140.8 (Ar-C). 
MS (EI) m/z (relative intensity): 192 (3%), 174 (11), 143 (90), 132 (100). 
HR-MS: 192.1149; Calculated value for C12H16O2: 192.1150 (0.6 ppm). 
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 Spectrum 29: 1H-NMR spectrum of compound 3c. 
 
Spectrum 30: 13C-NMR spectrum of compound 3c. 
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1-(2-fluorophenyl)-1,2-cyclopropanedimethanol (3d) 
 
Yield: 1.49 g (7.75 mmol) of (B)-2d gave 1.21 g (6.17 mmol, 80%) of (B)-3d as a 
pale yellow oil. 
Rf: 0.47 (50 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.81 (t, 1H, J=5.5Hz, H3b), 1.02 (dd, 1H, J=8.6Hz, 
J=5.5Hz, H3a), 1.64 (tdd, 1H, J=11.5Hz, J=8.6Hz, J=5.5Hz, H2), 3.02 (s, 2H, OH), 
3.38 (t, 1H, J=11.5Hz, H5), 3.51 (d, 1H, J=9.3Hz, H4), 4.05 (d, 1H, J=9.3Hz, H4), 4.15 
(dd, 1H, J=12.5Hz, J=5.5Hz, H5), 6.96-7.09 (m, 2H, Ar), 7.17-7.23 (m, 1H, Ar), 7.34-
7.39 (m, 1H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 16.3 (d, J=1.8Hz, C3), 24.6 (s, C2), 27.9 (s, C1), 63.2 
(s, C5), 66.9 (s, C4), 115.5 (d, J=21.9Hz, Ar-CH), 123.9 (d, J=3.6Hz, Ar-CH), 128.7 
(d, J=8.3Hz, Ar-CH), 130.5 (d, J=13.6Hz, Ar-C), 132.7 (d, J=4.2Hz, Ar-CH), 162.1 
(d, J=247.2Hz, Ar-C). 
(A)-3d: 
[ ]20Dα : +42.1º (c 0.24 in chloroform). 
(B)-3d: 
[ ]20Dα : -36.9º (c 0.29 in chloroform). 
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 Spectrum 31: 1H-NMR spectrum of compound 3d. 
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Spectrum 32: 13C-NMR spectrum of compound 3d. 
1-(3-fluorophenyl)-1,2-cyclopropanedimethanol (3e) 
 
Yield: 1.60 g (8.32 mmol) of (B)-2e gave 1.62 g (8.24 mmol, 99%) of (B)-3e as a 
yellow oil. 
Rf: 0.46 (50 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.76 (t, 1H, J=5.3Hz, H3b), 1.07 (dd, 1H, J=8.5Hz, 
J=5.3Hz, H3a), 1.63 (m, 1H, H2), 3.13 (s, 2H, OH), 3.36 (t, 1H, J=11.3Hz, H5), 3.52 
(d, 1H, J=11.9Hz, H4), 4.17 (m, 2H, H4 H5), 6.86-6.92 (m, 1H, Ar), 7.05-7.20 (m, 2H, 
Ar), 7.22-7.27 (m, 1H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 17.2 (s, C3), 26.2 (s, C2), 31.9 (s, C1), 63.3 (s, C5), 67.1 
(s, C4), 113.5 (d, J=21.0Hz, Ar-CH), 115.9 (d, J=21.5Hz, Ar-CH), 124.5 (d, J=1.6Hz, 
Ar-CH), 129.7 (d, J=8.4Hz, Ar-CH), 146.6 (d, J=7.1Hz, Ar-C), 162.7 (d, J=245.6Hz, 
Ar-C). 
(A)-3e: 
[ ]20Dα : +39.6º (c 0.24 in chloroform). 
(B)-3e: 
[ ]20Dα : -34.2º (c 0.26 in chloroform). 
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 Spectrum 33: 1H-NMR spectrum of compound 3e. 
Spectrum 34: 13C-NMR spectrum of compound 3e. 
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1-(4-fluorophenyl)-1,2-cyclopropanedimethanol (3f) 
 
Yield: 0.919 g (4.78 mmol) of (B)-2f gave 0.920 g (4.69 mmol, 98%) of (B)-3f as a 
oil. 
Rf: 0.53 (50 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.74 (t, 1H, J=5.3Hz, H3b), 1.03 (dd, 1H, J=8.6Hz, 
J=5.3Hz, H3a), 1.60 (tdd, 1H, J=11.5Hz, J=8.6Hz, J=5.3Hz, H2), 2.86 (s, 2H, OH), 
3.24-3.44 (m, 1H, H5), 3.52 (d, 1H, J=11.9Hz, H4), 4.07 (d, 1H, J=11.9Hz, H4), 4.16 
(dd, 1H, J=11.5Hz, J=5.3Hz, H5), 6.93-7.02 (m, 2H, Ar), 7.30-7.37 (m, 2H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 16.8 (s, C3), 25.8 (s, C2), 31.7 (s, C1), 63.5 (s, C5), 67.6 
(s, C4), 115.1 (d, J=21.3Hz, C8), 130.9 (d, J=8.0Hz, C7), 139.6 (d, J=3.2Hz, C6), 161.6 
(d, J=245.1Hz, C9). 
MS (EI) m/z (relative intensity): 196 (1%), 178 (7), 147 (77), 136 (74), 109 (100). 
HR-MS: 196.0904; Calculated value for C11H13FO2: 196.0900 (-2.5 ppm). 
(B)-3f: 
[ ]20Dα : -39.3º (c 0.29, chloroform). 
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 Spectrum 35: 1H-NMR spectrum of compound 3f. 
Spectrum 36: 13C-NMR spectrum of compound 3f. 
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1-(4-methoxyphenyl)-1,2-cyclopropanedimethanol (3g) 
 
Yield: 1.14 g (5.58 mmol) of (B)-2g gave 0.855 g (4.10 mmol, 74%) of (B)-3g as a 
pale oil. 
Rf: 0.59 (50 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.72 (t, 1H, J=5.2Hz, H3b), 1.01 (dd, 1H, J=8.5Hz, 
J=5.2Hz, H3a), 1.63 (m, 1H, H2), 3.38 (t, 1H, J=12.0Hz, H5), 3.51 (d, 1H, J=11.8Hz, 
H4), 3.64 (s, 2H, OH), 3.77 (s, 3H, H10), 4.09 (d, 1H, J=11.8Hz, H4), 4.15 (dd, 1H, 
J=12.0Hz, J=5.2Hz, H5), 6.82-6.94 (m, 2H, Ar), 7.25-7.31 (m, 2H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 16.7 (C3), 25.7 (C2), 31.7 (C1), 55.3 (C10), 63.6 (C5), 
67.8 (C4), 113.7 (Ar-CH), 113.8 (Ar-CH), 130.4 (Ar-CH), 132.2 (Ar-CH), 135.9 (Ar-
C), 158.4 (Ar-C). 
MS (EI) m/z (relative intensity): 208 (16%), 190 (29), 177 (38), 159 (100), 148 (56), 
121 (46). 
HR-MS: 208.1101; Calculated value for C12H16O3: 208.1099 (-1.0 ppm). 
(A)-3g: 
[ ]20Dα : +37.4º (c 0.23, chloroform). 
(B)-3g: 
[ ]20Dα : -23.2º (c 0.19, chloroform). 
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 Spectrum 37: 1H-NMR spectrum of compound 3g. 
 
Spectrum 38: 13C-NMR spectrum of compound 3g. 
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1-(3,4-dichlorophenyl)-1,2-cyclopropanedimethanol (3h) 
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Yield: 1.51 g (7.25 mmol) of (A)-2h gave 1.49 g (7.02 mmol, 97%) of (A)-3h as a 
yellow oil. 
Rf: 0.46 (50 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.75 (t, 1H, J=5.5Hz, H3b), 1.03 (dd, 1H, J=8.7Hz, 
J=5.5Hz, H3a), 1.54 (m, 1H, H2), 3.29 (t, 1H, J=11.5Hz, H5), 3.46 (d, 1H, J=12.0Hz, 
H4), 3.58 (s, 2H, OH), 4.00 (d, 1H, J=12.0Hz, H4), 4.10 (dd, 1H, J=11.5Hz, J=5.5Hz, 
H5), 7.17 (dd, 1H, J=8.3Hz, J=2.1Hz, Ar), 7.32 (d, 1H, J=8.3Hz, Ar), 7.44 (d, 1H, 
J=2.1Hz, Ar). 
13C-NMR (75 MHz; CDCl3) δ 17.0 (C3), 26.0 (C2), 31.4 (C1), 63.1 (C5), 66.9 (C4), 
128.5 (Ar-CH), 130.1 (Ar-CH), 130.5 (Ar-C), 131.1 (Ar-CH), 132.0 (Ar-C), 144.4 
(Ar-C). 
MS (EI) m/z (relative intensity): 246/248/250 (3%/2/1), 215/217/219 (12/7/1), 
186/188/190 (87/82/26), 173/175/177 (49/31/7), 163 (100), 159 (63). 
HR-MS: 246.0210; Calculated value for C11H12Cl2O2: 246.0214 (2.0 ppm). 
(B)-3h: 
[ ]20Dα : +32.8º (c 0.54 in chloroform). 
Compound 3h is known in the literature, but only as (1R,2S).4 
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 Spectrum 39: 1H-NMR spectrum of compound 3h. 
 
Spectrum 40: 13C-NMR spectrum of compound 3h. 
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7.4 1-Aryl-3-(4-methoxybenyl)-3-azabicyclo[3.1.0] hexanes (4) 
General procedure 
Diol 3 (1 eq.) was dissolved in ethyl acetate (4 mL/mmol of compound 3). i-Pr2NEt 
(2.5 eq.) and MsCl (2.2 eq.) were added. The reaction was stirred at ambient 
temperature for 1 hour. The reaction mixture was diluted with ethyl acetate (20 mL) 
and washed with HCl (1 M, 40 mL) and brine (40 mL), and then dried over 
MgSO4(s). The solution was concentrated in vacuo and dissolved in dry THF (6.5 
mL/mmol of compound 3). Dry potassium carbonate (3.2 eq.) and 4-
methoxybenzylamine (3 eq.) were added, and the mixture was refluxed for 18 h. The 
solvent was removed in vacuo, and the residue partially dissolved in ethyl acetate (40 
mL). The solids were filtered off, and the solution dried over MgSO4(s) and 
concentrated in vacuo. The compound 4 was purified by flash chromatography (0-30 
% ethyl acetate in hexane). 
NMR analysis 
An in-depth NMR analysis is done on compound 4g (Fig. 10) for the N-protected 
bicyclic amines 4. 
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Figure 10: The structure of compound 4g. 
The aromatic signals and the signals for the –OMe groups in the 1H-NMR spectrum 
are easily identified together with the corresponding signals in the 13C-NMR spectrum 
using the HMQC spectrum. The aromatic signals are not analysed further, and no 
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distinction between the two –OMe signals is attempted. The only aliphatic quaternary 
signal in the 13C-NMR spectrum is assigned to C1. The signals for H2, H4, H5, H6 and 
H12 are then assigned in the following way. The C5 signal is the only methine signal in 
the DEPT spectrum, and the corresponding H5 signal is found using the HMQC 
spectrum. The signal for H12 is two closely spaced dublets coupling only to each other 
in the COSY spectrum. The signals for H2 and H4 are shifted downfield because of the 
adjacent nitrogen atom, and only H4 show coupling to H5. The difference between H4a 
and H4b; and H6a and H6b is accomplished by comparing coupling constants to H5 with 
the expected values from Karplus’ rule. The DEPT, HMQC and COSY spectra are 
included in the appendix. The proton coupling pattern between protons H4, H5 and H6 
is summarised in Table 14.  
Table 14: The proton coupling pattern in compound 4g. 
δ (in ppm) Assignment JH-H Couples to 
7.5 Hz H5 0.71 H6a 
4.0 Hz H6b 
4.0 Hz H5 1.44 H6b 
4.0 Hz H6a 
7.9 Hz H6a 
4.0 Hz H6b 
1.60 H5 
4.0 Hz H4b 
8.5 Hz H4a 2.52 H4b 
4.0 Hz H5 
3.03 H4a 8.5 Hz H4b 
 
 
3-(4-methoxybenzyl)-1-(2-methylphenyl)-3-azabicyclo[3.1.0]hexane 
(4a) 
 
Yield: 1.39 g (7.22 mmol) of (A)-3a gave 0.597 g (2.03 mmol, 22%) of (A)-4a as a 
colourless oil. 
Rf: 0.52 (20 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.70 (dd, 1H, J=8.0Hz, J=3.9HZ, H6a), 1.48 (t, 1H, 
J=3.9Hz, H6b), 1.65 (td, 1H, J=8.0Hz, J=3.9Hz, H5), 2.41 (s, 3H, H13), 2.42 (d, 1H, 
J=8.7Hz, H2), 2.70 (dd, 1H, J=8.8Hz, J=3.9Hz, H4b), 3.14 (d, 1H, J=8.8Hz, H4a), 3.17 
(d, 1H, J=8.7Hz, H2), 3.61 (d, 1H, J=12.9Hz, H14), 3.65 (d, 1H, J=12.9Hz, H14), 3.83 
(s, 3H,  H19), 6.85-6.89 (m, 2H, Ar), 7.13-7.17 (m, 3H, Ar), 7.22-7.32 (m, 3H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 14.2 (C6), 19.7 (C13), 23.0 (C5), 31.1 (C1), 55.0 (C4), 
55.2 (C19), 58.4 (C14), 59.5 (C2), 113.5 (C16), 125.7 (Ar-CH), 126.7 (Ar-CH), 129.7 
(C17), 130.1 (Ar-CH), 130.3 (Ar-CH), 132.0 (Ar-C), 138.6 (Ar-C), 140.0 (Ar-C), 
158.5 (C18). 
(A)-4a: 
[ ]20Dα : +79.0º (c 0.20 in chloroform). 
(B)-4a: 
[ ]20Dα : -77.3º (c 0.26 in chloroform). 
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 Spectrum 41: 1H-NMR spectrum of compound 4a. 
 
Spectrum 42: 13C-NMR spectrum of compound 4a. 
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3-(4-methoxybenzyl)-1-(3-methylphenyl)-3-azabicyclo[3.1.0]hexane 
(4b) 
 
Yield: 1.15 g (5.99 mmol) of (A)-3b gave 0.746 g (2.54 mmol, 42%) of (A)-4a as a 
colourless oil. 
Rf: 0.58 (20 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.77 (dd, 1H, J=7.9Hz, J=3.9Hz, H6a), 1.51 (t, 1H, 
J=3.9Hz, H6b), 1.69 (td, 1H, J=7.9Hz, J=3.9Hz, H5), 2.31 (s, 3H, H13), 2.54 (dd, 1H, 
J=8.7Hz, J=3.9, H4b), 2.61 (d, 1H, J=8.5Hz, H2), 3.06 (d, 1H, J=8.7Hz, H4a), 3.28 (d, 
1H, J=8.5Hz, H2), 3.64 (d, 1H, J=13.0Hz, H14), 3.69 (d, 1H, J=13.0Hz, H14), 3.79 (s, 
3H,  H19), 6.82-6.87 (m, 2H, Ar), 6.90-7.02 (m, 3H, Ar), 7.13-7.18 (m, 1H, Ar), 7.21-
7.26 (m, 2H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 17.1 (C6), 21.4 (C13), 24.6 (C5), 30.5 (C1), 54.9 (C4), 
55.2 (C19), 58.3 (C2), 58.4 (C14), 113.5 (C16), 123.3 (Ar-CH), 126.4 (Ar-CH), 127.0 
(Ar-CH),  128.1 (Ar-CH), 129.7 (C17), 132.0 (Ar-C), 137.8 (Ar-C), 143.0 (Ar-C), 
158.6 (C18). 
(A)-4a: 
[ ]20Dα : +78.3º (c 0.24 in chloroform). 
(B)-4a: 
[ ]20Dα : -87.1º (c 0.24 in chloroform). 
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 Spectrum 43: 1H-NMR spectrum of compound 4b. 
 
Spectrum 44: 13C-NMR spectrum of compound 4b. 
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3-(4-methoxybenzyl)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane 
(4c) 
 
Yield: 1.15 g (5.96 mmol) of (A)-3c gave 0.764 g (2.71 mmol, 45%) of (A)-4c as a 
white solid. 
Rf: 0.58 (20 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.66 (dd, 1H, J=7.9Hz, J=3.8HZ, H6a), 1.39 (t, 1H, 
J=3.8Hz, H6b), 1.56 (td, 1H, J=7.9Hz, J=3.8Hz, H5), 2.21 (s, 3H, H11), 2.42 (dd, 1H, 
J=8.6Hz, J=3.8Hz, H4b), 2.49 (d, 1H, J=8.4Hz, H2), 2.95 (d, 1H, J=8.6Hz, H4a), 3.15 
(d, 1H, J=8.4Hz, H2), 3.54 (d, 1H, J=13.0Hz, H12), 3.59 (d, 1H, J=13.0Hz, H12), 3.70 
(s, 3H,  H17), 6.74-6.78 (m, 2H, Ar), 6.92-7.00 (m, 4H, Ar), 7.12-7.15 (m, 2H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 16.8 (C6), 20.9 (C11), 24.5 (C5), 30.3 (C1), 55.0 (C4), 
55.2 (C17), 58.4 (C12), 58.6 (C2), 113.5 (C15), 126.3 (Ar-CH), 128.9 (Ar-CH), 129.6 
(Ar-CH),  131.5 (Ar-C), 135.1 (Ar-C), 140.1 (Ar-C), 158.5 (C16). 
MS (EI) m/z (relative intensity): 293 (34%), 172 (8), 144 (4), 129 (7), 121 (100). 
Melting point: (A)-4c: 38-40 ºC (from ethyl acetate: hexane). 
(A)-4a: 
[ ]20Dα : +37.9º (c 0.28 in chloroform). 
(B)-4a: 
[ ]20Dα : -82.3º (c 0.35 in chloroform). 
- 100 - 
 Spectrum 45: 1H-NMR spectrum of compound 4c. 
 
Spectrum 46: 13C-NMR spectrum of compound 4c. 
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3-(4-methoxybenzyl)-1-(2-fluorophenyl)-3-azabicyclo[3.1.0]hexane 
(4d) 
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Yield: 1.18 g (6.00 mmol) of (B)-3d gave 0.584 g (1.96 mmol, 33%) of (B)-4d as a 
colourless oil. 
Rf: 0.59 (20 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.78 (dd, 1H, J=7.9Hz, J=3.9HZ, H6a), 1.49 (t, 1H, 
J=3.9Hz, H6b), 1.73 (td, 1H, J=7.9Hz, J=3.9Hz, H5), 2.52 (d, 1H, J=8.5Hz, H2), 2.63 
(dd, 1H, J=8.6Hz, J=3.9Hz, H4b), 3.09 (d, 1H, J=8.6Hz, H4a), 3.22 (d, 1H, J=8.5Hz, 
H2), 3.59 (d, 1H, J=12.9Hz, H13), 3.63 (d, 1H, J=12.9Hz, H13), 3.82 (s, 3H,  H18), 
6.84-6.89 (m, 2H, Ar), 6.97-7.09 (m, 2H, Ar), 7.16-7.20 (m, 4H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 14.0 (d, J=0.9Hz, C6), 22.7 (d, J=1.6Hz, C5), 27.2 (s, 
C1), 54.8 (s, C4), 55.2 (s, C18), 58.3 (C13), 59.0 (d, J=2.0Hz, C2), 113.5 (s, C16), 115.4 
(d, J=22.0Hz, C9), 123.8 (d, J=3.5Hz, Ar-CH), 127.9 (d, J=8.2Hz, Ar-CH), 129.3 (d, 
J=13.9Hz, C7), 129.6 (s, C16), 130.8 (d, J=4.7Hz, Ar-CH), 131.6 (s, C14), 158.5 (C17), 
164.0 (d, J=247.0Hz, C8). 
(A)-4a: 
[ ]20Dα : +88.6º (c 0.21 in chloroform). 
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 Spectrum 47: 1H-NMR spectrum of compound 4d. 
 
Spectrum 48: 13C-NMR spectrum of compound 4d. 
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3-(4-methoxybenzyl)-1-(3-fluorophenyl)-3-azabicyclo[3.1.0]hexane 
(4e) 
 
Yield: 1.69 g (8.62 mmol) of (A)-3e gave 0.631 g (2.12 mmol, 25%) of (A)-4e as a 
colourless oil. 
Rf: 0.54 (20 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.78 (dd, 1H, J=7.9Hz, J=3.9HZ, H6a), 1.55 (t, 1H, 
J=3.9Hz, H6b), 1.69 (td, 1H, J=7.9Hz, J=3.9Hz, H5), 2.52 (dd, 1H, J=8.7Hz, J=3.9Hz, 
H4b), 2.59 (d, 1H, J=8.5Hz, H2), 3.05 (d, 1H, J=8.7Hz, H4a), 3.25 (d, 1H, J=8.5Hz, 
H2), 3.58 (d, 1H, J=12.9Hz, H13), 3.64 (d, 1H, J=12.9Hz, H13), 3.79 (s, 3H,  H18), 
6.76-6.88 (m, 5H, Ar), 7.16-7.23 (m, 3H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 17.6 (s, C6), 25.3 (s, C5), 30.4 (d, J=2.2Hz, C1), 54.7 
(s, C4), 55.2 (s, C18), 57.9 (s, C2), 58.3 (C13), 112.4 (d, J=21.1Hz, Ar-CH), 113.1 (d, 
J=21.6Hz, Ar-CH), 113.6 (s, C15), 121.7 (d, J=2.7 Hz, C12), 129.6 (d, J=8.5Hz, C11), 
129.7 (s, C16), 132.0 (s, C14), 145.9 (d, J=7.5Hz, C7), 158.6 (s, C17), 162.9 (d, 
J=245.0Hz, C9). 
(A)-4e: 
[ ]20Dα : +90.5º (c 0.22 in chloroform). 
(B)-4e: 
[ ]20Dα : -87.6º (c 0.25 in chloroform). 
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 Spectrum 49: 1H-NMR spectrum of compound 4e. 
 
Spectrum 50: 13C-NMR spectrum of compound 4e. 
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3-(4-methoxybenzyl)-1-(4-fluorophenyl)-3-azabicyclo[3.1.0]hexane 
(4f) 
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Yield: 0.807 g (4.11 mmol) of (B)-3f gave 0.675 g (2.27 mmol, 55%) of (B)-4f as a 
white solid. 
Rf: 0.53 (20 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.74 (dd, 1H, J=7.9Hz, J=4.0HZ, H6a), 1.51 (t, 1H, 
J=4.1Hz, H6b), 1.65 (td, 1H, J=7.8Hz, J=3.8Hz, H5), 2.54 (dd, 1H, J=8.6Hz, J=3.6Hz, 
H4b), 2.55 (d, 1H, J=8.4Hz, H2), 3.06 (d, 1H, J=8.6Hz, H4a), 3.24 (d, 1H, J=8.4Hz, 
H2), 3.58 (d, 1H, J=12.9Hz, H11), 3.65 (d, 1H, J=12.9Hz, H11), 3.80 (s, 3H,  H16), 
6.84-6.89 (m, 2H, Ar), 6.92-7.00 (m, 2H, Ar), 7.06-7.12 (m, 2H, Ar), 7.21-7.26 (m, 
2H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 16.6 (s, C6), 24.5 (s, C5), 30.2 (s, C1), 54.9 (s, C4), 55.2 
(s, C16), 58.3 (s, C11), 58.7 (C2), 113.5 (s, C13), 114.9 (d, J=21.2Hz, C9), 128.0 (d, 
J=7.8Hz, C8), 129.6 (s, C14), 131.4 (s, C12), 138.7 (d, J=3.1Hz, C7), 158.5 (s, C15), 
161.1 (d, J=243.8Hz, C10). 
MS (EI) m/z (relative intensity): 297 (42%), 176 (11), 121 (100). 
HR-MS: 297.1522; Calculated value for C19H20FNO: 297.1529 (2.4 ppm). 
Melting point: (A)-4f: 67-70 ºC (from ethyl acetate: hexane). 
(B)-4f: 
[ ]20Dα : -88.5º (c 0.20 in chloroform). 
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 Spectrum 51: 1H-NMR spectrum of compound 4f. 
 
Spectrum 52: 13C-NMR spectrum of compound 4f. 
- 107 - 
3-(4-methoxybenzyl)-1-(4-methoxyphenyl)-3-azabicyclo[3.1.0]hexane 
(4g) 
 
Yield: 0.812 g (3.90 mmol) of (B)-3g gave 0.412 g (1.33 mmol, 34%) of (B)-4g as a 
white solid. 
Rf: 0.47 (20 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.71 (dd, 1H, J=7.9Hz, J=4.0HZ, H6a), 1.44 (t, 1H, 
J=4.0Hz, H6b), 1.60 (td, 1H, J=7.9Hz, J=4.0Hz, H5), 2.52 (dd, 1H, J=8.5Hz, J=4.0Hz, 
H4b), 2.54 (d, 1H, J=8.5Hz, H2), 3.03 (d, 1H, J=8.5Hz, H4a), 3.21 (d, 1H, J=8.5Hz, 
H2), 3.56 (d, 1H, J=12.9Hz, H12), 3.62 (d, 1H, J=12.9Hz, H12), 3.78 (s, 3H, OMe), 
3.79 (s, 3H, OMe), 6.79-6.85 (m, 4H, Ar), 7.05-7.08 (m, 2H, Ar), 7.20-7.24 (m, 2H, 
Ar). 
13C-NMR (75 MHz; CDCl3) δ 16.2 (C6), 24.2 (C5), 30.1 (C1), 55.1 (C4), 55.2 (OMe), 
55.3 (OMe), 58.4 (C12), 59.0 (C2), 113.5 (Ar-CH), 113.7 (Ar-CH), 127.7 (Ar-CH), 
129.6 (Ar-CH), 131.5 (Ar-C), 135.1 (Ar-C), 157.7 (Ar-CO), 158.5 (Ar-CO). 
MS (EI) m/z (relative intensity): 309 (30%), 188 (13), 160 (19), 121 (100). 
Melting point: (B)-4g: 79-82 ºC (from ethyl acetate: hexane). 
(A)-4g: 
[ ]20Dα : -89.5º (c 0.19 in chloroform). 
(B)-4f: 
[ ]20Dα : +84.2º (c 0.19 in chloroform). 
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 Spectrum 53: 1H-NMR spectrum of compound 4g. 
 
Spectrum 54: 13C-NMR spectrum of compound 4g. 
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1-(3,4-dichlorophenyl)-3-(4-methoxybenzyl)-3-
azabicyclo[3.1.0]hexane (4h) 
 
Yield: 1.25 g (5.12 mmol) of (A)-3h gave 1.36 g (3.90 mmol, 76%) of (A)-4h as a 
pale yellow oil. 
Rf: 0.62 (20 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 0.79 (dd, 1H, J=7.9Hz, J=3.9HZ, H6a), 1.58 (t, 1H, 
J=3.9Hz, H6b), 1.71 (td, 1H, J=7.9Hz, J=3.9Hz, H5), 2.56 (m, 2H, H2 H4b), 3.08 (d, 
1H, J=8.8Hz, H4a), 3.25 (d, 1H, J=8.5Hz, H2), 3.60 (d, 1H, J=12.9Hz, H13), 3.67 (d, 
1H, J=12.9Hz, H13), 3.83 (s, 3H, H18), 6.85-6.89 (m, 2H, Ar), 6.93-6.98 (m, 1H, Ar), 
7.20-7.26 (m, 3H, Ar), 7.29-7.35 (m, 1H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 17.3 (C6), 25.2 (C5), 30.1 (C1), 54.7 (C4), 55.2 (C18), 
57.8 (C2), 58.2 (C13), 113.6 (C16), 125.7 (Ar-CH), 128.4 (Ar-CH), 129.4 (Ar-C), 129.6 
(C15),  130.0 (Ar-CH), 132.0 (Ar-C), 132.1 (Ar-C),  143.6 (Ar-C), 158.6 (C17). 
MS (EI) m/z (relative intensity): 242/244/246 (100%/65/11), 212/214/216 (59/43/10), 
184/186/188 (25/20/6), 163 (40), 146(57), 128 (34). 
HR-MS: 347.0843; Calculated value for C19H19Cl2NO: 347.0844 (0.3 ppm). 
(A)-4g: [ ]20Dα : +93.8º (c 0.39 in chloroform). 
(B)-4f: 
[ ]20Dα : -114.2º (c 0.26 in chloroform). 
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 Spectrum 55: 1H-NMR spectrum of compound 4h. 
 
Spectrum 56: 13C-NMR spectrum of compound 4h. 
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7.5 1-Aryl-3-azabicyclo[3.1.0]hexanes (5) 
General procedure 
The N-protected amine 4 (1 eq.) was dissolved in dichloromethane (4.5 mL/mmol of 
compound 4), and α-chloroethyl chloroformate (1.3 eq.) was added. The mixture was 
stirred at ambient temperature for 20 minutes. The solvent was evaporated in vacuo, 
and the residue was dissolved in methanol (11.5 mL/mmol of compound 4). The 
solution was refluxed for 40 minutes, and the solvent evaporated in vacuo. The solids 
obtained were recrystallised from acetonitrile to give the target compound 5 as the 
hydrochloride salt. 
NMR analysis 
An in-depth NMR analysis is done on compound 5c (Fig. 11) for the target 
compounds 5. 
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Figure 11: The structure of compound 5c. 
The signals in the 1H-NMR spectrum are divided into four groups: the three protons 
on the cyclopropane ring; the four protons on the aromatic ring; the three protons on 
the methyl group; and the four protons on the remaining methylene groups. The 
singlet for the methyl group is easily recognised and the corresponding signal in the 
13C-NMR spectrum is found by correlation in the HMQC spectrum. Then the C5 
signal is identified in the DEPT spectrum, and the corresponding H5 signal found in 
the HMQC spectrum. The C6 signal is identified as the methylene signal with the 
lowest ppm value in the DEPT spectrum, and the H6 signals are found in the HMQC 
spectrum. The two remaining methylene signals from the 135-DEPT spectrum are 
- 112 - 
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identified as C2 and C4, and the corresponding proton signals are found in the HMQC 
spectrum. 
Carbon signals for C8 and C9 are the only signals left in the DEPT spectrum, and it is 
not necessary to distinguish between them. The two quaternary carbon signals in the 
aromatic region are assigned to C7 and C10, and again not distinguished. The final 
signal in the 13C-NMR spectrum is assigned to C1. 
To distinguish between H2 and H4 the coupling constant between one of the H4 signals 
and the H5 signal is found in the COSY spectrum. The distinction between H4a and 
H4b is accomplished by comparing the coupling constants to H5 with the expected 
values from Karplus’ rule. The distinction between protons H6a and H6b was not 
possible in most compounds 5, because the peaks were on top of each other. The 
DEPT, HMQC and COSY spectra are included in the appendix. 
 
 
1-(2-methylphenyl)-3-azabicyclo[3.1.0]hexane (5a) 
 
Yield: 0.307 g (1.05 mmol) of (B)-4a gave 0.122 g (0.34 mmol, 32%) of (B)-5a as a 
white solid. 
1H-NMR (300 MHz; CDCl3) δ 1.13 (m, 1H, H6), 1.22 (m, 1H, H6), 2.11 (td, 1H, 
J=8.4Hz, J=4.2Hz, H5), 2.42 (s, 3H, H13), 3.32 (m, 1H, H2), 3.57 (d, 1H, J=11.5Hz, 
H4a), 3.67 (d, 1H, J=11.5Hz, H2), 3.77 (dd, 1H, J=11.5Hz, J=4.2Hz, H4b), 7.15-7.21 
(m, 3H, Ar), 7.33-7.37 (m, 1H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 15.0 (C6), 19.7 (C13), 23.7 (C5), 32.4 (C1), 49.2 (C4), 
52.3 (C2), 127.4 (Ar-CH), 129.2 (Ar-CH), 131.2 (Ar-CH), 131.6 (Ar-CH), 137.0 (Ar-
C), 139.6 (Ar-C). 
Melting point: (A)-5a: 254-257 ºC (from acetonitrile). 
(A)-5a: 
[ ]20Dα : +59.0º (c 0.20 in methanol). 
(B)-5a: 
[ ]20Dα : -60.0º (c 0.23 in methanol). 
Compound 5a is known, but only as a racemic mixture.2 
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Spectrum 57: 1H-NMR spectrum of compound 5a. 
 
Spectrum 58: 13C-NMR spectrum of compound 5a. 
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1-(3-methylphenyl)-3-azabicyclo[3.1.0]hexane (5b) 
 
Yield: 0.700 g (2.39 mmol) of (A)-4b gave 0.178 g (0.85 mmol, 36%) of (A)-5b as a 
white solid. 
1H-NMR (300 MHz; CDCl3) δ 1.15 (m, 1H, H6), 1.22 (m, 1H, H6), 2.13 (td, 1H, 
J=8.5Hz, J=4.4Hz, H5), 2.32 (s, 3H, H13), 3.52 (d, 1H, J=11.5Hz, H4a), 3.59 (dd, 1H, 
J=11.3Hz, J=1.3Hz, H2), 3.67 (dd, 1H, J=11.5Hz, J=4.4Hz, H4b), 3.74 (d, 1H, 
J=11.3Hz, H2), 7.06-7.12 (m, 3H, Ar), 7.19-7.24 (m, 1H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 15.0 (C6), 19.7 (C13), 23.7 (C5), 32.4 (C1), 49.2 (C4), 
52.3 (C2), 127.4 (Ar-CH), 129.2 (Ar-CH), 131.2 (Ar-CH), 131.6 (Ar-CH), 137.0 (Ar-
C), 139.6 (Ar-C). 
Melting point: (A)-5b: 118-120 ºC (from acetonitrile). 
(A)-5b: 
[ ]20Dα : +50.6º (c 0.18 in methanol). 
(B)-5b: 
[ ]20Dα : -53.9º (c 0.19 in methanol). 
Compound 5b is known in the literature, but only as a racemic mixture.2 
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 Spectrum 59: 1H-NMR spectrum of compound 5b. 
 
Spectrum 60: 13C-NMR spectrum of compound 5b. 
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1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane (5c) 
 
Yield: 0.764 g (2.60 mmol) of (A)-4c gave 0.393 g (1.88 mmol, 72%) of (A)-5c as a 
white solid. 
1H-NMR (300 MHz; CDCl3) δ 1.13 (m, 1H, H6), 1.18 (m, 1H, H6), 2.07 (m, 1H, H5), 
2.28 (s, 3H, H11), 3.49 (d, 1H, J=11.4Hz, H4a), 3.55 (dd, 1H, J=11.3Hz, J=1.3Hz, H2), 
3.64 (dd, 1H, J=11.4Hz, J=3.9Hz, H4b), 3.71(d, 1H, J=11.3Hz, H2), 7.11-7.18 (m, 4H, 
Ar). 
13C-NMR (75 MHz; CDCl3) δ 15.9 (C6), 21.1 (C11), 24.2 (C5), 32.2 (C1), 49.1 (C4), 
52.2 (C2), 128.2 (Ar-CH), 130.4 (Ar-CH), 136.7 (Ar-C), 138.1 (Ar-C). 
Melting point: (A)-5c: 199-204 ºC (from acetonitrile). 
(A)-5c: 
[ ]20Dα : 62.9º (c 0.21 in methanol). 
(B)-5c: 
[ ]20Dα : -57.4º (c 0.19 in methanol). 
Compound 5c is known in the literature.2 
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 Spectrum 61: 1H-NMR spectrum of compound 5c. 
 
Spectrum 62: 13C-NMR spectrum of compound 5c. 
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1-(2-fluorophenyl)-3-azabicyclo[3.1.0]hexane (5d) 
 
Yield: 0.553 g (1.86 mmol) of (A)-4d gave 0.215 g (1.00 mmol, 54%) of (A)-5d as a 
white solid. 
1H-NMR (300 MHz; CDCl3) δ 1.19-1.27 (m, 2H, H6), 2.17 (m, 1H, H5), 3.49 (dd, 1H, 
J=11.4Hz, J=1.0Hz, H2), 3.56 (d, 1H, J=11.5Hz, H4), 3.70 (m, 2H, H2 H4), 7.09-7.20 
(m, 2H, Ar), 7.30-7.41 (m, 2H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 14.5 (s, C6), 23.3 (s, C5), 28.7 (s, C1), 48.9 (s, C4), 52.0 
(d, J=3.6Hz, C2), 116.6 (d, J=21.6Hz, C9), 125.8 (d, J=3.5Hz, Ar-CH), 126.2 (d, 
J=14.0Hz, C7), 131.0 (d, J=8.4Hz, Ar-CH), 131.8 (d, J=3.8Hz, Ar-CH), 163.7 (d, 
J=245.8Hz, C8). 
Melting point: (A)-5d: 204-207 ºC (from acetonitrile). 
(A)-5d: 
[ ]20Dα : +50.0º (c 0.31 in methanol). 
(B)-5d: 
[ ]20Dα : -45.7º (c 0.21 in methanol). 
- 120 - 
 Spectrum 63: 1H-NMR spectrum of compound 5d. 
 
Spectrum 64: 1H-NMR spectrum of compound 5d. 
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1-(3-fluorophenyl)-3-azabicyclo[3.1.0]hexane (5e) 
N
H
1
2
3
4
5
6
7
12
11
10
9
8
F
 
Yield: 0.592 g (1.99 mmol) of (A)-4e gave 0.135 g (0.63 mmol, 32%) of (A)-5e as a 
white solid. 
1H-NMR (300 MHz; CDCl3) δ 1.21-1.30 (m, 2H, H6), 2.19 (m, 1H, H5), 3.53 (d, 1H, 
J=11.6Hz, H4a), 3.63 (dd, 1H, J=11.4Hz, J=1.3Hz, H2), 3.68 (dd, J=11.6Hz, J=4.0Hz, 
1H, H4b), 3.78 (d, J=11.4Hz, H2), 6.96-7.14 (m, 3H, Ar), 7.32-7.39 (m, 1H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 16.6 (s, C6), 24.8 (s, C5), 32.1 (d, J=2.2Hz, C1), 49.0 
(s, C4), 51.7 (s, C2), 115.0 (d, J=21.3Hz, Ar-CH), 115.1 (d, J=22.5Hz, Ar-CH), 124.0 
(d, J=2.9Hz, Ar-CH), 131.7 (d, J=8.5Hz, Ar-CH), 142.8 (d, J=7.8Hz, C7), 164.4 (d, 
J=244.9Hz, C9). 
Melting point: (A)-5e: 166-168 ºC (from acetonitrile). 
(A)-5e: 
[ ]20Dα : +70.0º (c 0.20 in methanol). 
(B)-5e: 
[ ]20Dα : -77.4º (c 0.19 in methanol).  
Compound 5e is known in the literature, but only as a racemic mixture.2 
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 Spectrum 65: 1H-NMR spectrum of compound 5e. 
 
Spectrum 66: 13C-NMR spectrum of compound 5e. 
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1-(4-fluorophenyl)-3-azabicyclo[3.1.0]hexane (5f) 
N
H
1
2
3
4
5
6
7
8
9
10
9
8 F
 
Yield: 0.577 mg (1.94 mmol) of (B)-4f gave 0.172 g (0.80 mmol, 41%) of (B)-5f as a 
white solid. 
1H-NMR (300 MHz; CDCl3) δ 1.15-1.25 (m, 2H, H6), 2.12 (td, 1H, J=8.5Hz, 
J=4.4Hz, H5), 3.51 (d, 1H, J=11.5Hz, H4), 3.57 (dd, 1H, J=11.4Hz, J=1.3Hz, H2), 
3.69 (dd, J=11.5Hz, J=4.4Hz, 1H, H4), 3.74 (d, J=11.4Hz, H2), 7.03-7.09 (m, 2H, Ar), 
7.32-7.37 (m, 2H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 15.8 (s, C6), 24.3 (s, C5), 31.9 (s, C1), 49.1 (s, C4), 52.3 
(s, C2), 116.5 (d, J=21.8Hz, C9), 130.5 (d, J=8.2Hz, C8), 135.8 (d, J=3.2Hz, C7), 163.4 
(d, J=244.6, C10). 
MS (EI) m/z (relative intensity): 177 (100%), 162 (14), 148 (77), 147 (57), 136 (22), 
133 (40). 
Melting point: (B)-5f: 181-183 ºC (from acetonitrile). 
(B)-5f: 
[ ]20Dα : -56.3º (c 0.19 in methanol). 
Compound 5f is known in the literature, but only as a racemic mixture.2 
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 Spectrum 67: 1H-NMR spectrum of compound 5f. 
 
Spectrum 68: 13C-NMR spectrum of compound 5f. 
- 125 - 
1-(4-methoxyphenyl)-3-azabicyclo[3.1.0]hexane (5g) 
N
H
1
2
3
4
5
6
7
8
9
10
9
8 O
11
 
Yield: 0.256 g (0.83 mmol) of (A)-4g gave 0.117 g (0.52 mmol, 63%) of (A)-5g as a 
white solid. 
1H-NMR (300 MHz; CDCl3) δ 1.11 (m, 2H, H6), 1.19 (m, 1H, H6a), 2.04 (td, 1H, 
J=8.4Hz, J=4.3Hz, H5), 3.50 (m, 1H, H4a), 3.53 (m, 1H, H2), 3.67 (dd, J=11.5Hz, 
J=4.3Hz, 1H, H4b), 3.70 (d, J=11.3Hz, H2), 3.76 (s, 3H, H11), 6.86-6.91 (m, 2H, Ar), 
7.21-7.26 (m, 2H, Ar). 
13C-NMR (75 MHz; CDCl3) δ 15.5 (C6), 24.0 (C5), 32.0 (C1), 49.2 (C4), 52.5 (C2), 
57.8 (C11), 115.2 (C9), 129.8 (C8), 131.5 (C7), 160.5 (C10). 
MS (ESI) m/z (relative intensity): 190 (100%). 
Melting point: (B)-5g: 214-215 ºC (from acetonitrile). 
(A)-5g: 
[ ]20Dα : +58.5º (c 0.20 in methanol). 
(B)-5g:  
[ ]20Dα : -57.0º (c 0.20 in methanol). 
Compound 5g is known in the literature.48 
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 Spectrum 69: 1H-NMR spectrum of compound 5g. 
 
Spectrum 70: 13C-NMR spectrum of compound 5g. 
- 127 - 
1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane (5h) 
 
Yield: 0.114 g (3.27 mmol) of (A)-4h gave 0.606 mg (2.29 mmol, 70%) of (A)-5h as 
a white solid. 
1H-NMR (300 MHz; CDCl3) δ 1.16 (m, 1H, H6), 1.30 (m, 1H, H6), 2.22 (td, 1H, 
J=8.6Hz, J=4.4Hz, H5), 3.52 (d, 1H, J=11.5Hz, H4a), 3.61 (d, 1H, J=11.4Hz, H2), 3.68 
(dd, 1H, J=11.5Hz, J=4.4Hz, H4b), 3.76 (d, J=11.4Hz, H2), 7.25 (dd, 2H, J=8.4Hz, 
J=2.2Hz, H12), 7.50 (d, 2H, J=8.4Hz, H11), 7.52 (d, 1H, J=2.1Hz, H8). 
13C-NMR (75 MHz; CDCl3) δ 16.4 (C6), 24.8 (C5), 31.7 (C1), 48.9 (C4), 51.6 (C2), 
128.3 (C12), 130.5 (C8), 131.8 (C11), 132.1 (Ar-C), 133.6 (Ar-C), 140.8 (Ar-C). 
MS (ESI) m/z (relative intensity):  
HR-MS: 227.026291  Calculated value for C11H11Cl2N: 227.026855 (2.5 ppm) 
Melting point: (A)-5h: 182-184 ºC  (from acetonitrile). 
(A)-5h: 
[ ]20Dα : +55.7 º (c 0.23 in methanol). 
Compound 5h is known in the literature.49 
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 Spectrum 71: 1H-NMR spectrum of compound 5h. 
 
Spectrum 72: 13C-NMR spectrum of compound 5h. 
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7.6 tert-Butyl allylcarbamate (42)50 
 
Allylamine 40 (0.23 mL, 3.0 mmol, 1.0 eq.) was dissolved in CH2Cl2 (10 mL). Boc2O 
41 (654.0 mg, 3.0 mmol, 1.0 eq.) was added in one portion, and the mixture was 
stirred at ambient temperature for 18 h. The solvent was evaporated in vacuo to yield 
42 as colourless crystals (467.2 mg, 2.972 mmol, 99 %). 
Rf: 0.14 (10 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 1.41 (s, 9H, tBu), 3.70 (m, 2H, H1), 4.61 (s, 1H, NH), 
5.04-5.17 (m, 2H, H3), 5.73-5.86 (m, 1H, H2). 
13C-NMR (75 MHz; CDCl3) δ 28.3 (CH3), 43.1 (C1), 79.3 (C-(CH3)3), 115.6 (C3), 
134.9 (C2), 155.7 (C=O). 
Compound 42 is known in the literature.51 
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 Spectrum 73: 1H-NMR spectrum of compound 42. 
 
Spectrum 74: 13C-NMR spectrum of compound 42. 
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7.7 2-(Bromomethyl)-2-(4-bromophenyl)-1,3-dioxolane (45a)40 
Br
Br
OO
 
2-bromo-1-(4-bromophenyl)ethanone 39a (13.9 g, 50.0 mmol, 1.0 eq.), ethylene 
glycol (3.23 g, 52.0 mmol, 1.04 eq.) and p-toluenesulfonic acid (0.025 g, 0.13 mmol, 
0.0025 eq.) were dissolved in toluene (25 mL). The reaction was refluxed, and the 
water removed using a Dean and Stark water separator. After 1 hour the solvent was 
removed in vacuo, and the residues dissolved in ethyl acetate (60 mL). The solution 
was washed subsequently with NaOH (1 M, 30 mL) and water (30 mL) and then dried 
over MgSO4(s). The crude was purified by flash chromatography (0-10 % ethyl 
acetate in hexane) to give the product 45a (9.13 g, 28.4 mmol, 57 %) as a white solid. 
Rf: 0.27 (10 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 3.59 (s, 2H, CH2Br), 3.80-3.91 (m, 2H, OCH2), 4.10-
4.21 (m, 2H, OCH2), 7.34-7.39 (m, 2H, Ar-CH), 7.45-7.50 (m, 2H, Ar-CH). 
13C-NMR (75 MHz; CDCl3) δ 37.7 (CH2Br), 65.8 (OCH2), 106.9, 123.0, 127.8 (Ar-
CH), 131.4 (Ar-CH), 138.7. 
Melting point: 79-81 ºC  (from ethyl acetate: hexane). 
Compound 45a is known in the literature.52 
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 Spectrum 75: 1H-NMR spectrum of compound 45a. 
 
Spectrum 76: 13C-NMR spectrum of compound 45a. 
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7.8 Dimethyl 2-diazomalonate (48)42, 53 
 
Dimethyl malonate 47 (1.06 g, 8.00 mmol, 1.0 eq.) was dissolved acetonitrile (50 mL) 
under inert atmosphere, and p-ABSA (1.96 g, 9.60 mmol, 1.2 eq.) was added. The 
solution was cooled to 0 ºC, and triethylamine (3.40 mL, 24.0 mmol, 3.0 eq.) was 
added dropwise. The reaction mixture was stirred at ambient temperature for 18 h. 
The solvent was removed in vacuo. The residue was dissolved in diethylether/hexane 
(1:1, 50 mL), and the solids filtered off. The filtrate was reduced in vacuo, and the 
resulting oil was purified by flash chromatography (0-30 % ethyl acetate in hexane) to 
give the product 48 as a pale yellow oil (855.1 mg, 67.6 %). 
Rf: 0.19 (10 % ethyl acetate in hexane). 
1H-NMR (300 MHz; CDCl3) δ 3.70 (s, 6H, Me). 
13C-NMR (75 MHz; CDCl3) δ 52.1 (Me), 65.3 (C=N2), 161.0 (C=O). 
MS (ESI) m/z (relative intensity): 158 (31%), 127 (14), 99 (9), 69 (18), 59 (100). 
Compound 48 is known in the literature.54 
- 134 - 
 Spectrum 77: 1H-NMR spectrum of compound 48. 
 
Spectrum 78: 1H-NMR spectrum of compound 48. 
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7.9 N,N-Bis(tert-butoxycarbonyl)allylamine (49) 
N
O O
O
O
 
To a solution of allylamine 40 (6.60 mL, 87.6 mmol, 1.0 eq.) and Boc2O (42.0 g, 193 
mmol, 2.2 eq.) in acetonitrile (50 mL) was carefully added DMAP (4.28 g, 35.0 
mmol, 0.40 eq.). The solution was refluxed for 5 days. The solvent was evaporated in 
vacuo, and the residue purified by flash chromatography (0-20 % ethyl acetate in 
hexane) to give the product 49 (8.13 g, 31.6 mmol, 36 %). 
1H-NMR (300 MHz; CDCl3) δ 1.42 (s, 18H, Me), 4.10 (td, 2H, J=5.5 Hz, J=1.5Hz, 
H1), 5.02-5.10 (m, 2H, H3), 5.70-5.83 (m, 1H, H2). 
13C-NMR (75 MHz; CDCl3) δ 27.9 (Me), 48.3 (C1), 82.1 (C-(CH3)3), 116.0 (C3), 
133.6 (C2), 152.1 (C=O). 
Compound 49 is known in the literature.55 
- 136 - 
 Spectrum 79: 1H-NMR spectrum of compound 49. 
 
Spectrum 80: 13C-NMR spectrum of compound 50. 
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7.10 Dimethyl 2-((bis(tert-butoxycarbonyl)amino)methyl) 
cyclopropane-1,1-dicarboxylate (50) 
 
To a solution of N,N-bis(tert-butoxycarbonyl)allylamine 49 (0.309 g, 1.20 mmol, 1.2 
eq.) and Rh2TMA4 (31 mg, 0.05 mmol, 5 mol%) in refluxing 1,2-dichloroethane (10 
mL) was added dimethyl 2-diazomalonate 48 (0.158 g, 1.00 mmol, 1.0 eq.) dissolved 
in 1,2-dichloroethane (2 mL). After 3 h, the reaction mixture was concentrated in 
vacuo and the product was purified by flash chromatography (5 % ethyl acetate in 
hexane) to give the product 50 (20.0 mg, 0.05 mmol, 5 %). 
1H-NMR (300 MHz; CDCl3) δ 1.40 (dd, 1H, J=9.0Hz, J=4.7Hz, H), 1.48 (s, 18H, 
Boc), 1.62 (dd, 1H, J=7.6Hz, J=4.7Hz, H), 2.09-2.30 (m, 1H, H), 3.36 (dd, 1H, 
J=14.4Hz, J=9.0Hz, H), 3.69 (s, 3H, COOMe), 3.74 (s, 3H, COOMe), 3.85 (dd, 1H, 
J=14.4Hz, J=5.0Hz, H). 
- 138 - 
 Spectrum 81: 1H-NMR spectrum of compound 50. 
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8 Appendix 
 
Spectrum 82: 135-DEPT spectrum of compound 2i. 
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 Spectrum 83: HMQC spectrum of compound 2i. 
 
Spectrum 84: COSY spectrum of compound 2i. 
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 Spectrum 85: 135-DEPT spectrum of compound 3d. 
 
Spectrum 86: HMQC spectrum of compound 3d. 
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 Spectrum 87: COSY spectrum of compound 3d. 
 
Spectrum 88: 135-DEPT spectrum of compound 4g. 
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 Spectrum 89: HMQC spectrum of compound 4g. 
 
Spectrum 90: COSY spectrum of compound 4g. 
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 Spectrum 91: 135-DEPT spectrum of compound 5c. 
 
Spectrum 92: HMQC spectrum of compound 5c. 
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 Spectrum 93: COSY spectrum of compound 5c. 
- 147 - 
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X-ray crystallography data for compound 5f 
Crystal data 
 
C11H13FN+·Cl–     V = 1049.6 (3) Å3 
Mr = 213.67      Z = 4 
Orthorhombic, P212121    Mo Kα 
a = 6.9146 (10) Å     μ = 0.34 mm−1 
b = 7.8048 (11) Å     T = 296 (2) K 
c = 19.448 (3) Å     0.50 × 0.36 × 0.25 mm 
 
Data collection 
 
Bruker Apex II CCD 
diffractometer     2292 independent reflections 
Absorption correction: multi-scan 
SADABS (Sheldrick, 1996)    2244 reflections with I > 2σ(I) 
Tmin = 0.766, Tmax = 0.919    Rint = 0.028 
6726 measured reflections 
 
Refinement 
 
R[F2 > 2σ(F2)] = 0.025   H atoms treated by a mixture of 
independent and constrained refinement 
wR(F2) = 0.066     Δρmax = 0.38 e Å−3 
S = 1.05      Δρmin = −0.17 e Å−3 
2292 reflections  Absolute structure: Flack H D (1983),  
133 parameters  Acta Cryst. A39, 876-881 
      Flack parameter: −0.03 (5) 
- 149 - 
9 References 
1. G. L. Patrick, An Introduction to Medicinal Chemistry, Oxford University 
Press, Oxford, 2001, 2nd ed., a) pp. 142-145, b) pp. 336-339. 
2. J. W. Epstein, H. J. Brabander, W. J. Fanshawe, C. M. Hofmann, T. C. 
McKenzie, S. R. Safir, A. C. Osterberg, D. B. Cosulich and F. M. Lovell, 
Journal of Medicinal Chemistry, 1981, 24, 481-490. 
3. J. W. Epstein, A. C. Osterberg and B. Regan, NIDA Research Monograph, 
1982, 41, 93-98. 
4. F. Xu, J. A. Murry, B. Simmons, E. Corley, K. Fitch, S. Karady and D. 
Tschaen, Organic Letters, 2006, 8, 3885-3888. 
5. M. Zhang, F. Jovic, T. Vickers, B. Dyck, J. Tamiya, J. Grey, A. Tran Joe, A. 
Fleck Beth, R. Pick, C. Foster Alan and C. Chen, Bioorganic & medicinal 
chemistry letters, 2008, 18, 3682-3686. 
6. D. L. Nelson and M. M. Cox, Principles of Biochemistry, W. H. Freeman and 
Company, New York, 2005, 4th edition, p. 428. 
7. W. T. Blows, The Journal of neuroscience nursing : journal of the American 
Association of Neuroscience Nurses, 2000, 32, 234-238. 
8. J. Birtwistle and D. Baldwin, British journal of nursing (Mark Allen 
Publishing), 1998, 7, 832-834, 836, 838-841. 
9. J. W. Epstein, A. C. Osterberg and H. J. Brabander, American Cyanamid Co., 
USA, Patent US, US4435419, 1984. 
10. B. K. Madras, G. M. Miller and A. J. Fischman, Biological Psychiatry, 2005, 
57, 1397-1409. 
11. C. Sanchez and J. Hyttel, Cell Mol Neurobiol, 1999, 19, 467-489. 
12. P. H. Silverstone, Journal of Clinical Psychiatry, 2004, 65, 19-28. 
13. S. B. Ross and A. L. Renyi, Acta Pharmacologica et Toxicologica, 1975, 36, 
56-66. 
14. L. A. Sorbera, J. Castaner and P. A. Leeson, Drugs of the Future, 2005, 30, 7-
10. 
15. K. B. Thor, Dynogen Pharmaceuticals, Inc., USA, Patent WO, 
WO2005117872, 2005. 
16. R. I. Wang, R. P. Johnson, J. C. Lee and E. M. Waite, J Clin Pharmacol, 1982, 
22, 160-164. 
17. P. Skolnick, P. Popik, A. Janowsky, B. Beer and A. S. Lippa, European 
Journal of Pharmacology, 2003, 461, 99-104. 
18. A. S. Lippa and J. W. Epstein, USA, Patent US, US2003045567, 2003. 
19. W. J. Fanshawe, J. W. Epstein, L. S. Crawley, C. M. Hofmann and S. R. Safir, 
American Cyanamid Co., USA, Patent DE, DE2740562, 1978. 
20. A. S. Lippa and J. W. Epstein, Dov Pharmaceutical, Inc., USA, Patent US, 
US6372919, 2002. 
21. B. Beer and J. W. Epstein, American Cyanamid Company, USA, Patent US, 
US6204284, 2001. 
22. C. L. Anderton, S. Bacchi, S. Beato and F. Sartor, Glaxo Group Limited, UK, 
Patent WO, WO2008024143, 2008. 
23. E. G. Corley, B. Simmons, F. Xu and J. A. Murry, Dov Pharmaceutical, Inc., 
USA, Patent WO, WO2008024143, 2008. 
- 150 - 
24. A. S. Lippa, J. W. Epstein, J. T. Tizzano and A. Basile, Dov Pharmaceutical, 
Inc., USA, Patent WO, WO2008063673, 2008. 
25. G. Shapiro, J. Moncuso, T. Pierre, S. Leit, R. Deziel, S. David, C. Richard, Y. 
A. Chantigny and B. Patrick, Methygene Inc., Can.; En Vivo Pharmaceuticals, 
Inc., Patent WO, WO2008055068, 2008. 
26. J. P. Tizzano, D. S. Stribling, D. Perez-Tilve, A. Strack, A. Frassetto, R. Z. 
Chen, T. M. Fong, L. Shearman, P. A. Krieter, M. H. Tschop, P. Skolnick and 
A. S. Basile, Journal of Pharmacology and Experimental Therapeutics, 2008, 
324, 1111-1126. 
27. A. Marrazzo, A. Pappalardo, O. Prezzavento, F. Vittorio and G. Ronsisvalle, 
ARKIVOC (Gainesville, FL, United States), 2004, 156-169. 
28. A. Marrazzo, O. Prezzavento, M. S. Pappalardo, E. Bousquet, M. Iadanza, V. 
W. Pike and G. Ronsisvalle, Farmaco, 2002, 57, 45-53. 
29. W. J. Fanshawe, J. W. Epstein, L. S. Crawley, C. M. Hofmann and S. R. Safir, 
American Cyanamid Co., USA, Patent US, US4088652, 1978. 
30. Y. G. Perron and W. F. Minor, Journal of Organic Chemistry, 1959, 24, 1165-
1167. 
31. H. Roggen, J. Kehler, T. B. Stensbol and T. Hansen, Bioorg. Med. Chem. 
Lett., 2007, 17, 2834-2837. 
32. K. Yamaguchi, Y. Kazuta, H. Abe, A. Matsuda and S. Shuto, Journal of 
Organic Chemistry, 2003, 68, 9255-9262. 
33. P. G. M. Wuts and T. W. Greene, Greene's Protective Groups in Organic 
Synthesis, John Wiley & Sons, Inc., Hoboken, New Jersey, 2007, 4th ed., pp. 
818-819. 
34. B. M. Trost, M. J. Krische, R. Radinov and G. Zanoni, Journal of the 
American Chemical Society, 1996, 118, 6297-6298. 
35. B. Hungerhoff, S. S. Samanta, J. Roels and P. Metz, Synlett, 2000, 77-79. 
36. S. D. Bull, S. G. Davies, G. Fenton, A. W. Mulvaney, R. S. Prasad and A. D. 
Smith, Perkin 1, 2000, 3765-3774. 
37. B. V. Yang, D. O'Rourke and J. Li, Synlett, 1993, 195-196. 
38. J. L. Garcia Ruano, S. A. Alonso de Diego, M. R. Martin, E. Torrente and A. 
M. Martin Castro, Organic Letters, 2004, 6, 4945-4948. 
39. B. Quiclet-Sire and S. Z. Zard, Chemical Communications (Cambridge, 
United Kingdom), 2006, 1831-1832. 
40. D. R. Paulson, A. L. Hartwig and G. F. Moran, Journal of Chemical 
Education, 1973, 50, 216-217. 
41. S. Darses and J.-P. Genet, Chemical Reviews (Washington, DC, United 
States), 2008, 108, 288-325. 
42. M. L. Rosenberg, in Department of Chemistry, University of Oslo, Oslo, 
Norway, 2005, p. 205. 
43. H. Lebel, J.-F. Marcoux, C. Molinaro and A. B. Charette, Chemical Reviews 
(Washington, DC, United States), 2003, 103, 977-1050. 
44. D. D. Perrin, W. L. F. Armarego and D. R. Perrin, Purification of Laboratory 
Chemicals, Pergamon Press, Oxford, 1980. 
45. Y. Kazuta, R. Tsujita, K. Yamashita, S. Uchino, S. Kohsaka, A. Matsuda and 
S. Shuto, Bioorganic & Medicinal Chemistry, 2002, 10, 3829-3848. 
46. B. Bonnaud, H. Cousse, G. Mouzin, M. Briley, A. Stenger, F. Fauran and J. P. 
Couzinier, Journal of Medicinal Chemistry, 1987, 30, 318-325. 
- 151 - 
47. J. Tamiya, B. Dyck, M. Zhang, K. Phan, B. A. Fleck, A. Aparicio, F. Jovic, J. 
A. Tran, T. Vickers, J. Grey, A. C. Foster and C. Chen, Bioorg. Med. Chem. 
Lett., 2008, 18, 3328-3332. 
48. P. Skolnick, A. Basile and Z. Chen, Dov Pharmaceutical, Inc., USA, Patent 
WO, WO2006096810, 2006. 
49. S. Phil and Z. Chen, Dov Pharmaceutical, Inc., USA, Patent WO, 
WO2008013856, 2008. 
50. A. L. Castelhano, A. Krantz, D. H. Pliura, M. C. Venuti and L. M. De Young, 
Syntex (U.S.A.), Inc., USA, Patent EP, EP237082, 1987. 
51. R. Varala, S. Nuvula and S. R. Adapa, Journal of Organic Chemistry, 2006, 
71, 8283-8286. 
52. A. R. Patel and J. F. Oneto, Journal of Pharmaceutical Sciences, 1963, 52, 
588-592. 
53. J. S. Baum, D. A. Shook, H. M. L. Davies and H. D. Smith, Synthetic 
Communications, 1987, 17, 1709-1716. 
54. D. B. Ramachary, V. V. Narayana and K. Ramakumar, Tetrahedron Letters, 
2008, 49, 2704-2709. 
55. R. D. Connell, T. Rein, B. Aakermark and P. Helquist, Journal of Organic 
Chemistry, 1988, 53, 3845-3849. 
 
 
